Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 1 of 47 
  
PHASE I, OPEN -LABEL TRIAL TO EVALUATE THE SAFETY AND 
IMMUNOGENICITY OF SNS -301 IN CANCER PATIENTS   
 
 
Study product:   SNS-301 
Protocol number:   SNS0216 
IND:                               16963 
Phase:  1 
Version:   5.0 
Amendment Date :  12 June 2018  
 
      Study Sponsor:  
        Sensei Biotherapeutics, Inc.  
620 Professional Drive 
 
Gaithersburg, MD  20879  
 
Regulatory Statement  
This study will be performed  in compliance with the protocol and in accordance with Good Clinical 
Practice (International Conference on Harmonization, Guidance E6, 1996), principles of human 
subject protection, and applicable country -specific regulatory requirements.  
Confidentiality Statement 
The information in this document contains trade secrets and commercial information that are 
privileged or confidential and may not be disclosed unless such disclosure is required by applicable 
laws and regulations. In any event, persons for whom this information is disclosed must be 
informed that the information is privileged or confidential and may not be further disclosed by 
them. These restrictions on disclosure will apply equally to all future information supplied to you 
that is indicated as p rivileged or confidential.  
This Study Protocol is produced on a word- processing system and bears no signatures. The 
approval of the Study Protocol is documented in a separate Approval Document.  
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 2 of 47 
 SPONSORS PROTOCOL SIGNATURE P AGE  
 
 
Sponsor:  Sensei Biotherapeutics, Inc.  
Protocol Title  Phase I, Open -Label Trial To  Evaluate The  Safety And Immunogenicity 
Of SNS -3011 In Cancer Patients  
Protocol Number  SNS0216 
Protocol Version  
Amendment Date:  Version 5.0  
12 June 2018  
 
 I approved the protocol and confirm that the protocol follows the current ICH/GCP guidelines.  
 
 
  
_______________________________________________________________________________  
Steve Fuller, Ph.D .  Date  
Chief Operating Officer  
Sensei Biotherapeutics, Inc.  
  
                                                      
1 Due to the company changing their name from Panacea Pharmaceuticals to Sens ei Biotherapeutics , the 
drug PAN -301-1 was renamed  SNS-301.  
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 3 of 47 
 TABLE OF CONTENTS  
1. SYNOPSIS ................................................................................................................................. 6 
1.1 TIME AND EVENTS SCHEDULES  ............................................................................... 13 
2. TERMS, ACRONYMS, ABB REVIATIONS  ....................................................................... 15 
3. INTRODUCTION  .................................................................................................................. 17 
3.1 PRIMARY DISEASE AND STUDY TREATMENT INFORMATION  ........................................... 17 
3.2 PREVIOUS NON-CLINICAL EXPERIENCE  ........................................................................... 18 
3.3 CURRENT CLINICAL EXPERIENCE  ..................................................................................... 19 
3.4 STUDY RATIONALE  ........................................................................................................... 21 
4. STUDY OBJECTIVES AND ENDPOINTS  ......................................................................... 22 
4.1 STUDY OBJECTIVES  .......................................................................................................... 22 
4.1.1  Primary  ..................................................................................................................... 22 
4.1.2  Secondary  ................................................................................................................. 22 
4.2 STUDY ENDPOINTS  ............................................................................................................ 23 
4.2.1  Primary  ..................................................................................................................... 23 
4.2.2  Secondary  ................................................................................................................. 23 
4.2.3  Clinic al secondary endpoints  .................................................................................... 23 
4.2.4  Pharmacodynamic secondary endpoints  .................................................................. 23 
5. INVESTIGATIONAL PLAN ................................................................................................ 24 
5.1 OVERALL STUDY DESIGN AND PLAN DESCRIPTION  ......................................................... 24 
5.2 SELECTION OF STUDY POPULATION  ................................................................................. 26 
5.2.1  Inclusion Criteria  ...................................................................................................... 26 
5.2.2  Exclusion Criteria  ..................................................................................................... 26 
5.2.3  Removal of Patients from Treatment or Assessment  ................................................. 27 
5.2.4  Enrollment Holds  ...................................................................................................... 28 
5.3 STUDY TREATMENT  .......................................................................................................... 28 
5.3.1  Treatments Administered  .......................................................................................... 28 
5.3.2  Identity of the Study Treatment  ................................................................................. 28 
5.3.2.1  Study Treatment Details  .................................................................................... 28 
5.3.2.2  Study Treatment Administration  ...................................................................... 28 
5.3.2.3  Handling and Storage of Study Treatment  ...................................................... 28 
5.3.2.4  Handling/Responsibilities  ................................................................................... 29 
5.3.2.5  Study Investigational Treatment Management and Disposal  ......................... 29 
5.3.3  Method of Assigning Patients to Study Groups  ........................................................ 29 
5.3.4  Selection of Doses for the Study  ............................................................................... 30 
5.3.5  Selection and Timing of Dose for Each Patient  ........................................................ 30 
5.3.5.1  Dose -limiting toxicities  ....................................................................................... 31 
5.3.5.2  Dose delay or reduction  ...................................................................................... 31 
5.4 BLINDING  .......................................................................................................................... 31 
5.4.1  Prior and Concomitant Treatment  ............................................................................ 31 
5.4.1.1  Allowed concomitant treatments  ....................................................................... 31 
5.4.1.2  Prohibited Medications or Treatments During Study  ..................................... 32 
5.4.2  Study Treatment Accountability and Compliance Procedures  ................................. 32 
5.5 SAFETY AND EFFICACY VARIABLES AND STUDY ASSESSMENTS  ..................................... 32 
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 4 of 47 
 5.5.1  Pre-study Assessments  .............................................................................................. 32 
5.5.1.1  HAAH expression of archived tissue  ................................................................. 32 
5.5.1.2  HAAH expression in serum  ............................................................................... 32 
5.5.2  Study visits and assessments ..................................................................................... 32 
5.5.2.1  Screening period (Day - 56 (+ 7 days) to Day 0)  ................................................ 32 
5.5.2.2  Dose -escalation Treatment: Day 1  ..................................................................... 33 
5.5.2.3  Dose -escalation Treatment: Day 8 ± 2 days  ...................................................... 33 
5.5.2.4  Dose -escalation Treatment: Day 15 ± 2 days  .................................................... 33 
5.5.2.5  Study Visits: Day 22, Day 43 ± 3 days  ............................................................... 33 
5.5.2.6  Additional treatment: Every additional 21 days ± 3 days  if indicated  ........... 34 
5.5.2.7  Follow up and End of Study (EOS): 28 days ± 3 days  after last treatment for 
a total of 6 months  ............................................................................................................... 34 
5.5.3  Safety Measurements  ................................................................................................ 34 
5.5.3.1  Clinical Laboratory Assessments  ...................................................................... 34 
5.5.3.2  Immunological blood collection  ......................................................................... 35 
5.5.3.3  Administration site reaction  .............................................................................. 36 
5.5.3.4  ECOG performance score  .................................................................................. 36 
5.5.3.5  Adverse Events (AE)  ........................................................................................... 36 
5.5.3.6  Serious Adverse Event (SAE)  ............................................................................ 38 
5.5.3.7  Unexpected fatal or life -threatening suspected adverse reaction reports  ...... 39 
5.5.3.8  Clinical Laboratory Assessments  ...................................................................... 39 
5.5.4  Efficacy (Clinical) Measurements ............................................................................. 40 
5.5.4.1  PSA assessment  ................................................................................................... 40 
5.5.4.2  Treatment Failure  ............................................................................................... 40 
5.6 DATA QUALITY ASSURANCE  ............................................................................................ 40 
6. STATISTICAL METHODS AND DETERMINATION OF  SAMPLE SIZE .................. 40 
6.1 STATISTICAL AND ANALYTICAL PLANS  ........................................................................... 40 
6.2 DETERMINATION OF SAMPLE SIZE .................................................................................... 40 
7. ETHICS  ................................................................................................................................... 40 
7.1 INSTITUTIONAL REVIEW BOARD (IRB)  / ETHICS COMMITTEE  ......................................... 40 
7.2 ETHICAL CONDUCT OF THE STUDY  ................................................................................... 41 
7.3 PATIENT INFORMATION AND CONSENT  ............................................................................ 41 
7.4 PROTOCOL AMENDMENTS  ................................................................................................ 41 
7.5 CONFIDENTIALITY  ............................................................................................................ 41 
8. INVES TIGATORS AND STUDY ADMINISTRATIVE STRUCT URE  .......................... 42 
8.1 SPONSOR CONTACTS  ......................................................................................................... 42 
8.2 DATA HANDLING AND RECORDKEEPING  .......................................................................... 42 
8.2.1  Electronic Case Report Form (eCRF)  ...................................................................... 42 
8.2.2  Maintenance of Study Records  ................................................................................. 42 
8.3 FINAL REPORT  .................................................................................................................. 42 
8.4 PUBLICAT ION AND USE OF STUDY FINDINGS  ................................................................... 43 
8.5 LIABILITY AND INSURANCE  .............................................................................................. 43 
9. REFERENCE LIST ................................................................................................................ 44 
10. LIST O F APPENDICES  ........................................................................................................ 45 
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 5 of 47 
 APPENDIX A: ECOG PERFORMANCE STATUS  ................................................................... 46 
APPENDIX B: PRINCIPAL INVESTIGATOR SIGNATURE OF AGREEMENT PAGE  ... 47 
 
  
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 6 of 47 
 1. SYNOPSIS 
Protocol number:  SNS0216 
Protocol title:  Phase I, Open -Label Trial to Evaluate the Safety and Immunogenicity of 
SNS-301 in Cancer Patients  
Phase of development:  Phase I  
Objectives (Part 1):  Primary   
To determine the maximum tolerated dose (MTD) of SNS -301, based on the 
incidence of dose limiting toxicities (DLT) an d the maximum administered 
dose of SNS-301, when administered every 21 days in patients  with 
biochemically relapsed prostate cancer.  
 
Secon dary 
To assess the overall safety of SNS -301.  
Study design:  This is a Phase I, open- label, study of SNS -301, an HAAH- directed  
nanoparticle vaccine , given intra dermally in cohorts of patients  with 
biochemically relapsed prostate cancer , using a fixed dose -escalation schema 
every 21 days  to establish the MTD .  
Following informed consent and screening, archived prostate  tumor  tissue 
(if available), and patient  fresh serum will be tested for the expression of 
HAAH. Patients  who test positive for HAAH expression  in either archived 
tumor tissue  (if available), or fresh serum may be continued in the study . 
Baseline biochemical testing ( chemistry, complete blood count  [CBC] , 
coagulation panel, CH-50, and prostate -specif ic antigen [ PSA],) will be 
obtained prior to study treatment .  Patient s who are negative for HAAH in 
archived tumor tissue or fresh serum  can be followed for PSA levels over 
the next 6 months, and, if levels increase appreciably, they can be retested 
for HAAH. If HAAH is positive at any time within the 6 -month period, the 
patient  can be enrolled.  
Treatment will consist of single repeated doses of SNS -301 administered 
every 21 days for 3 doses. A traditional 3+3 dose -escalation schema will be 
used to determine  the MTD of SNS -301for the first 2 doses  and a modified 
dose-escalation schema for the remaining dose . Planned doses of SNS -301 
are 2.0 x 1010, 1.0 x 1011 and 3.0 x 1011 particles per administration  diluted 
to 1 mL and administered intradermally.  Additional patients  will be 
enrolled at the highest dose level until at least 6 patient s can be evaluated 
even if no DLTs are observed at the dose. Planned treatment may continue 
for two additional doses of SNS -301 administered every 21 days.  Serum 
and whole blood samples will be obtained on the day of study treatment , at 
Day 1, Day 8, Day 15, and Day 22 during the first cycle . For patients  who 
continue to receive study treatment , biochemical and immunologic testing 
will continue every 21 days.   
The MTD will be determined over the first 21- day interval following a 
single dose of SNS -301 in 3 dose cohorts. The MTD will be considered the 
dose level lower than the dose produc ing ≥2 DLT s in 3-6 patients . Patients  
who withdraw in cycle 1 for reasons ot her than safety or toxicity will be 
replaced. Any of the following, if jud ged to be associated with SNS-301 
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 7 of 47 
 (i.e., possibly -, probably -, or definitely related to), will be considered a DLT  
using the National Cancer Institute -Common Terminology Criteria for 
Adverse Events (NCI-CTCAE ) Version 4.03:  
1) Grade 4 non- hematological toxicities (excluding alope cia) of any 
duration  
2) Grade 3 non- hematologic (non-laboratory ) toxicity  lasting > 3 days 
despite optimal supportive care  
3) Any Grade 3 or Grade 4 non- hematologic laboratory value if: a). 
Medical intervention is required to treat the patient ; b), the 
abnormality leads to hospitalization; c). The abnormality persists for 
>1 week.  
4) Grade 4 hematologic toxicity , other than those specified in criteria 5 
and 6 below , lasting > 7 days  
5) Grade 3 or Grade 4 febrile neutropenia  of any duration  
6) Grade 3 thrombocytopenia in combination wi th a grade 3 or greater 
blood and lymphatic system disorder  
7) Grade 3 AST or ALT that is as sociated with a grade 2 rise in bilirubin  
The recommended Phase 2 dose (RP2D) will be de fined as the highest dose 
administered  if no MTD is observed.  
Dose cohorts will be enrolled sequentially  and no dose escalation will occur 
until all patients  in the current cohort complete the first 21- day cycle. After 
the first patient  in each cohort has demonstrated adequate safety and 
tolerability for at least 21 days, the next 2 patient s in the cohort may be 
enrolled. When at least 3 patient s have reached Day 21  if none of the first 3 
patient s experiences a DLT, then dose -escalation to the next level can begin.  
Multiple patient s can be in the screening phase but the first eligible patient  
able to be treated is assigned the treatment slot that is available for study.  
A safety assessment of administration site reactions (ASR)  will be made  by 
the Investigator at least 30 minutes  (or later)  following each dose  of study 
drug using the ( NCI-CTCAE V4 .03). Enrollment will be held  if an ASR  of 
grade 3 or greater (NCI -CTCAE  V4.03) is observed , until the event resolves. 
In the event enrollment is held for an ASR , the Sponsor  and Investigator  will 
evaluate the outcome of the ASR  and must agree to continued enrollment.  
In patient s who tolerate SNS -301, additional treatment may be continued 
with single doses of SNS-301 at the ir current dose level , to maintain 
geometric mean titer (GMT) of HAAH antibodies  to no less than 4 times th e 
baseline value  for at least six months  (9 injections) . Treatment will be 
terminated with  the 9th  injection or will  otherwise  be terminated at any time 
upon the observance of PSA do ubling < 90 days or occurrence of 
unacceptable toxicity . After termination, p atients will be followed for an 
additional 6 months with monthly PSA levels and imaging studies as needed. 
If an unacceptable rise is detected in the patient’s PSA levels following 
treatment discontinuation, patients shall be eligible for imm ediate 
resumption of therapy.  
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 8 of 47 
 Once the MTD/ RP2D  is determined , patient s receiving  ongoing treatment 
may be escalated to that dose for subsequent treatments. These patient s will 
continue to be followed for safety and biochemical PSA monitoring.  
Pharmacodyn amic s:  
Exploratory pharmacodynamic ( PD) analysis will be performed using dose, 
vaccine- specific antibody response (geometric mean of titer ), antigen-
specific T and B cell indices, and the relative expression of HAAH in each 
patient’s  tumor. The PD will be balanced and optimized to the degree of 
antigen -specific immune response and minimized for the production of 
regulatory immune processes.  
Other Safety:  
Safety will be evaluated by  the incidence and severity of ASR s, changes in 
biochemical safety measures, general incidence and types of AE s, serious 
adverse events (SAEs) , and other overt toxicities.  
Number of patients / 
centers:  This is a multi- center dose -escalation study with an extension study at the 
RP2D . Up to approximately 18 patie nts will be studied.  
Randomization 
procedure:  The study is an open- label, dose -escalating, non -randomized P hase 1 clinical 
study with a dose extension phase. No randomization will be performed.  
Inclusion criteria : 1. Signed and dated written Ethics Committee approved informed consent  
2. Men aged 21 to 85 years with a histologic diagnosis of prostate cancer 
with a biochemical relapse following definitive local therapy (RP or 
radiation therapy)  
3. Patients  are not eligible or are un willing to receive additional definitive 
therapy f ollowing relapse (either RP or radiation therapy )  
4. No prior  cytotoxic chemotherapy  for the current cancer  
5. Normal electrocardiogram ( ECG ) or ECG with no clinically significant 
findings  as determined by the Principal In vestigator  
6. Presence of biochemical ly relapsed  prostate cancer defined as either : 
1) PSA > 2 ng/mL 1 year following initial definitive treatment for 
prostate cancer:  or, 2) PSA doubling t ime (greater than 0. 2 ng/mL)  
< 12 months; or, 3) PSA velocity > 2 ng/mL/year at any  time following 
radical prostatectomy or radiation therapy .  
7. Positive expression of HAAH in either archived tumor tissue (if 
available)  or fresh serum  
8. No clinical or radiologic evidence of distant metastatic disease  as 
measured by pelvic M RI or CT scan in addition to bone scan. These 
studies will need to be performed within 56 +7 days prior to the start of 
the study.  
9. No history of immunosuppressive  disease. Active autoimmune disease 
is defined as any disease process that has specifically needed 
administration of immune suppressive and or cytoreductive therapy 
currently or within the last 1 year.  
10. No evidence  of active autoimmune  disease  
11. Able and willing to comply with all study  procedures  
  
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 9 of 47 
 Exclusion criteria : 1. PSA doubling time of < 3 months  
2. Participation in a clinical trial within 30 days of prior to enrollment  
3. Prior major surgery or radiation therapy within 4 weeks of enrollment  
4. Any illness or condition that in the opinion of the Investigator may 
affect the safety of the subject or the evalu ation of any study endpoint  
5. Screening blood counts of the following:  
Hematopoietic:  
Absolute neutrophil count <  1500/μL,  
Platelets < 100,000/μL,  
Hemoglobin <  9 g/dL;  
Liver/Metabolic:  
Alanine aminotransferase (ALT) and aspartate 
transaminase (AST) > 2.5 × ULN range,  
Total bilirubin >  2 × ULN,  
Albumin <  2.8 g/dL;  
Renal:  
Creatinine clearance < 50 mL/min as predicted by the 
Cockcroft -Gault formula  
6. Subjects whose partners are women of child- bearing potential 
(WOCBP ) must use an adequate method of birt h control while on study 
drug and at least for 3 weeks after discontinuation of study drug  
7. Current or anticipated concomitant immunosuppressive therapy 
(excluding non- systemic inhaled, topical skin and/or eye 
drop- containing corticosteroids)  
8. Any concurrent  condition requiring the continued use of systemic 
steroids (see above) or the use of immunosuppressive agents including 
methotrexate. All other systemic corticosteroids must be discontinued 
at least 4 weeks prior to first study treatment  
9. Receipt of any blood product within 1 month of enrollment  
10. Receipt of any vaccine within 4 weeks of enrollment  
11. Active drug or alcohol use or dependence that, in the opinion of the 
Investigator, would interfere with adherence to study requirements  
12. Been imprisoned or compulsorily detained (involuntarily incarcerated) 
for treatment of either a psychiatric or physical (i.e. infectious disease) 
illness  
13. Patients  who have a history of coagulopathies, thrombosis or 
who are receiving active anticoagulation for any condition, such 
as but not limited to, artificial heart valves, atrial fibrillation, etc.  
14. Any other conditions judged by the Investigator that would limit 
the evaluation of a subject  
Study Product  
Formulation  SNS-301 consists of lambda bacteriophages expressing HAA H-1λ on the 
head of the bacteriophage. The bacteriophages are prepared in a liquid 
formulation in phosphate -buffered saline, pH 7.4.  A 1mL dose filled in a 
3M® glass cartridge with a butyl rubber stopper and crimp cap seal.   
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 10 of 47 
 Route of 
administration:  Intradermally: vaccine to be delivered by a single- use 3M® hollow micro 
structured  transdermal system (hMTS) device.  
Dose regimen : Escalating doses of 2.0 x 1010 and 1.0 x 1011 particles will be administered to 
cohorts  of 3 patient s and 3.0 x 1011 particles will be administered to a cohort 
of 6 patients  every 21 days to assess the MTD.   The RP2D will be considered  
the MTD unless convincing safety, PD, or PK data suggest otherwise. At 
such a point, these data will be shared with the FDA and the RP2D  will be 
changed or additional dose escalation cohorts will be proposed If needed. 
Additional patients  will be enrolled at the highest dose level until at least 6 
patients can be evaluated even if no DLTs are observed at the dose.   
Patients  in the dose -escalation phase may continue to receive single doses of 
SNS-301 at their original dose level every 21 days or until the PSA doubling 
is < 90 days or unacceptable toxicity as determined by the Principal 
Investigator is observed (either for tha t patient  or in their dose cohort). Once 
the MTD/ RP2D  is determined, patients  receiving  ongoing treatment may be 
escalated to that dose for subsequent treatments  and receive a maximum of 
9 injections .  Patients who have received more than 9 injections due to the 
timing of the amendment limiting therapy to 6 months ( 9 doses), will be 
stopped at their last dose received and be followed for 6  months as with other 
patients.  These subjects will continue to be followed for safety and 
biochemical P SA monitoring  on a monthly basis for 6 months and are 
eligible to resume SNS-301 in case of increases in PSA doubling to < 90 
days or other evidence of disease progression and decline in immunological 
parameters.  
Study Endpoints : Primary endpoint:  
• To det ermine the MTD  
• Determine the RP2D if different than the MTD  
• Determine the DLTs associated with SNS -301 
Secondary endpoints:  
• Incidence of administration  site reactions  
• Biochemical safety and tolerability  
• Geometric mean titers of anti -HAAH antibodies by dose  
• Antigen -specific CTL responses by dose  
• Production of B cell and T cell response of interest  
Clinical secondary endpoints:  
• Change in the PSA velocity  
• Reduction in the PSA doubling time from pre -baseline  
Pharmacodynamic secondary endpoints:  
• Duration of antigen -specific anti -HAAH antibody titers  
• Changes in the amplitude or duration of the production of 
anti-HAAH antibodies  
• Correlation of  anti-HAAH titers and serum HAAH levels  
Study evaluations : Following informed consent signature,  archived prostate tumor tissue , and 
patient  serum will be tested for the expression of HAAH.  Only patients  who 
test positive for HAAH expression in archived tumor tissue (if available)  or 
fresh serum  may be continued in the study .  
The following evaluations will be performed:  
• Medical/oncology history, demographics: Screening  
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 11 of 47 
 • Signs and symptoms (baseline): Screening, Day 1  
• Physical examination: Screening and end of study ( EOS ) 
• Symptom -directed physical examination: Day 1, Day 8, Day 15, Day 
22, Day 43 and if additional treatment is given, at 21 -day intervals 
thereafter   
• Biochemical testing (chemistry, CBC, coagulation, CH50): 
Screening, Day 1, Day 22, Day 43 and if addi tional treatment is 
given at 21 -day intervals thereafter  and EOS  
• Bioc hemical testing (chemistry, CBC, coagulation, CH50) Day 8 
and Day  15 during cycle 1  
• Study treatment  administration : Day 1, Day 22, Day 43 and if 
additional treatment is given, at  21-day intervals thereafter  for a total 
of 9 injections.   Patients who have received more than 9 injections 
due to the timing of the amendment that details limiting therapy to 
6 months ( 9 doses), will be stopped at their last dose received and be 
followed for 6 months as with other patients.   Patients with off -
treatment evidence of progression and declining HAAH immune 
parameters during the 6- month observation period will have the 
option of immediately resuming therapy on study protocol.  
• Physician  administration  site assessment: Day 1, Day 8, Day 22, 
Day 43 and if  additional treatment is given at 21 -day intervals 
thereafter; and EO S 
• Safety evaluation of subject  to permit continued enrollment in each 
cohort Day 21for every first and last patient  in a dose level  
• Eastern Cooperative Oncology Group ( ECOG)  performance score: 
Screening, Day 1, Day 8, Day 15, Day 22, Day 43 and if additional 
treatment is given,  at 21 -day intervals thereafter; and EO S 
• Prostate -specific antigen ( PSA) assessment: Screening, Day 1, 
Day 22, Day 43 and if additional treatment is given, at 21 day  
intervals thereafter; until injection number 9 (or last dose otherwise)  
and EOS .  Afterwards PSA levels will be obtained on a monthly 
basis for a total of 6 months.  
• Immunologic blood collection: Screening, Day 1, Day 22, Day 43 
and if additional treatment is given, at 21 day intervals thereafter; 
until injection number 9 (or last dose otherwise)  and EOS . 
Afterwards levels will be obtained on a monthly basis  for a tota l of 
6 months.  
• Adverse events and concomitant medications (after the patient 
receives study drug) : Screening, Day 1, Day 8, Day 15, Day 22, 
Day 43 and if additional treatment is given, at 21 day intervals 
thereafter; until injection number 9 (or last dose  otherwise)  and EOS . 
Afterwards history  will be obtained on a monthly basis  for a total of 
6 months. 
• Vital signs, ECG: Screening, Day 1, Day  22, Day 43 and if additional 
treatment is given, at 21 day intervals thereafter; until injection 
number 9 (or last dose otherwise)  and EOS . Afterwards data  will be 
obtained on a monthly basis for a total of 6 months.  
Statistical analysis:  No formal statistical analysis  will be performed , however, statistical 
derivation of a ll data will be derived by dose cohort and displayed for 
inspection.  
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 12 of 47 
 For the dose -escalation phase of the study , cohorts of 3 or 6 patients will be 
screened, registered and treated at each dose level. The actual sample size 
may vary depending on the incide nce of DLT during Cycle 1 at a given dose 
level. Once the MTD/RP2D is determined, additional patients  may be 
accrued to provide for 6 patients  in the MTD cohort. Approximately, 
18 patients will be screened, registered and treated in the trial.  
The prima ry safety analysis will assess MTD and AE s, clinical laboratory 
tests, and tolerability, based on the combined evaluation of immunogenicity 
and incidence of DLTs  in each patient . 
Study duration:  The duration of the study for each patient  will include an up to 8- week  
screening phase, 21 -day study treatment  cycles for 9 cycles and  6 months of 
follow up including monthly PSAs and an end of study visit  (28 days post 
last dose of study treatment ).  
Patients may continue to receive single repeated doses of SNS -301 at their 
original dose level (or at the MTD when it is determined) every 21  days for 
a total of 9 doses or until the observance of PSA doubling <  90 days or 
unacceptable toxicity (either for that patient  or in their dose cohort). Patie nts 
who have received more than 9 injections due to the timing of the amendment 
limiting therapy to 6  months ( 9 doses), will be stopped at their last dose 
received and be followed for 6 months as with other patients.  Patients with 
evidence of progression and declining HAAH immune parameters during 
this 6 -month follow up period will have the option of immediately resuming 
therapy on study protocol.  
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 13 of 47 
 1.1 TIME AND EVENTS SCHE DULE S 
Table 1 : Time and Events Schedule  
Assessment  Screen 
(D-56+7e 
to D0)  Cycle 1 
Assessments  Cycle 2 -3 Additional 
Treatments  Follow -
up/End of 
study  
 D1 D8 
± 2 D15± 
2 D22 
± 3 D43 
± 3 Every 21 ± 
3 day Every 28 ± 3 
days after 
final 
treatment  for 
6 Months  
Signed Informed Consent  X        
HAAH assessmenta X        
Demographics  X        
Medical/Oncology 
History  X        
Tumor Burden 
Evaluationd X        
Baseline Signs and 
Symptoms  X        
Physical Examination  X       X 
Symptom -Directed 
Physical Examination   X X X X X X  
Vital Signs  X X X X X X X X 
ECOG Performance Score  X X X X X X X X 
ECG X X   X X X X 
PSA X X   X X X X 
Hematologyb X X X X X X X  
Chemistryb X X X X X X X  
Coagulation , CH50b X X X X X X X  
Study Treatment  
administration   X   X X X  
Physician Administration  
Site Assessment   X X  X X X  
Immunologic Blood 
Collectionc  X   X X X X 
Cohort enrol lment 
evaluation      X    
Concomitant Medications 
Collection   X X X X X X X 
Adverse Events 
Assessmentsf  X X X X X X X 
Abbreviations: ECG: electrocardiogram; ECOG : Eastern Cooperative Oncology Group;  PSA: prostate -specific antigen  
 
a  HAAH assessment : following informed consent, archived prostate  tumor tissue and patient  serum will be tested for the 
expression of HAAH.  Only patients  who test positive for HAAH expression  in archived tumor tissue (if available)  or 
fresh serum  may be continued in the study .  HAAH assessments are not subject to the  56-day screening window  and 
are valid for 6 months.   Patients  who are negative for HAAH may be followed for 6 months and if PSA rises over that 
period time, they can enroll in the study provided that tissue or fresh serum  is positive for HAAH  
b  Biochemical testing (chemistry, complete blood count , coagulation, and total complement CH50, ) to be obtained within 
14 days prior to study drug administration  if screening period is between 3 and 8 weeks.  PSA levels are also to be 
evaluated at screening and within 14 days prior to study drug administration if screening period is between 3 and 8 weeks.  
c  Immunol ogic blood collection : to be taken pre -dose on the day of study drug administration  (Day 1) and every 21 days 
thereafter . Following the 9th dose (or last dose otherwise) , PSA levels and other assessments will be followed on a 
monthly basis for 6 months.  Patients with evidence of progression and declining HAAH immune parameters will have 
the option of resuming therapy on the study protocol.  
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 14 of 47 
 d  Baseline radiological tumor burden evaluation consists of a baseline pel vic MRI or CT scan in addition to bone scan. 
These studies will need to be performed within 56 days (+ 7 days)  prior to the start of the study.  
e  Patients  that have a delay in screening beyond 56-days may be re-screened for randomization.  
f  Adverse events that occur post patient  receiving study drug.  Should Adverse event occur prior to patient  receiving 
study drug they will be capture d as Medical History.  
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 15 of 47 
 2.  TERMS, ACRONYMS, ABB REVIATIONS   
Term  Definition  
7-ADD  7-amino actinomycin D  
ADL  Activities of daily living  
AE Adverse e vent 
ALT  Alanine aminotransferase  
AP Alkaline phosphatase  
APC  Antigen -presenting cells  
ASR  Administration site reaction  
AST  Aspartate aminotransferase  
°C Celsius  
CBC Complete blood count  
CFR Code of Federal Regulations  
CFSE Carboxyfluorescein succinimidyl ester  
CH-50 Total complement activity  
CpG  5’-c-phosphate -G-3’(a DNA sequence)  
CTL  Cytotoxic CD8+ T -lymphocytes  
DLT  Dose-limiting toxicity  
DNA  Deoxyribonucleic acid  
ECG  Electrocardiogram  
ECOG  Eastern Cooperative Oncology Group  
eCRF  Electronic case report form  
EDC  Electronic data capture  
ELISA  Enzyme -linked immunosorbent assay  
EOS  End of study  
FDA Food and Drug Administration (U.S.)  
GMT  Geometric mean titer  
gpD  Head DNA stabilization protein of Bacteriophase lambda  
HAAH  Human aspartyl -asparaginyl -β-hydroxylase  
hMTS  3M® hollow microstructured transdermal system  
ICF Informed c onsent form 
IgG Immunoglobulin G  
IND Investigational New Drug  
IRB Institutional r eview board  
irRC  Immune -related response criteria  
kDa Kilodalton  
LVEF  Left ventricular ejection fraction  
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 16 of 47 
 Term  Definition  
MACS  Magnetic activated cell sorting  
MHC  Major histocompatibility complex 
mL Milliliters  
M0 Non-metastatic cancer  
M1 Metastatic cancer  
MTD  Maximum tolerable dose  
NCI-CTCAE 
V4.03  National Cancer Institute Common Terminology Criteria for 
Adverse Events V 4.03  
PBMC Peripheral blood monocytes  
SNS-301 HAAH bacteriophage lambda constructs: HAAH -1λ 
PSA Prostate -specific antigen  
RP Radical prostatectomy  
RP2D  Recommended phase 2 dose  
SAE  Serious adverse event  
WOCBP  Women of child- bearing potential  
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 17 of 47 
 3. INTRODUCTION  
3.1  Primary Disease and Study Treatment  Information  
Human aspartyl -asparaginyl -β-hydroxylase (HAAH), also known as aspartate- β-hydroxylase, 
is an ~86 kDa type 2 transmembrane protein that belongs to the α -ketoglutarate -dependent 
dioxygenase family [ 1]. It is a highly conserved enzyme, which catalyzes the hydroxylation 
of aspartyl and asparaginyl residues in epidermal growth factor -like domains of proteins 
including Notch and homologs [ 2]. HAAH was initially identified in a novel screen to identify 
cell surface proteins up-regulated in liver cancer. It has subsequently been detected in a diverse 
array of solid and blood cancers, including: liver, bil e duct, brain, breast, colon, prostate, 
ovary, pancreas, and lung cancers as well as leukemia. HAAH is not found in significant 
quantities in normal tissue or in proliferative disorders.   
Over -expression of HAAH has been demonstrated to be sufficient to i nduce cellular 
transformation, increase cellular proliferation and cellular motility  and suppression of HAAH 
expression ( small interfering ribonucleic acid ) or neutralized activity ( monoclonal antibodies ) 
returns cancer cells to a normal phenotype . In canc er cells,  it has been shown to be translocated 
to the cellular surface where it is not normally located. Because HAAH is an embryonic 
antigen, and as such presents self -antigen tolerance, it is relatively difficult to elicit a rob ust 
immune response agains t it. Thus, we posited that effective priming of antigen -presenting  
cells (APC)  by HAAH antigen is an essenti al step to overcome tolerance. Indeed, in vitro  
activation of dendritic cells with HAAH, prior to re -administration to patients  has shown 
promising results for liver cancer therapy [ 3]. Unfortunately, this process is cumbersome, 
expensive, time consuming and impractical for mass scale immunotherapy.   
Bacteriophage display is a simple, inexpensive and practical way of achieving favorable 
presentation of peptides to the immune system. The phage contains  deoxyribonucleic acid 
(DNA)  fragments that present the phage CpG motifs , which are known to stimulate the innate 
immune response and activate the major histocompatibility class ( MHC ) class II pathway in 
APC . Previous findings have revealed that recombinant bacteriophage can prime strong CD8+ 
T-lymphocyte (CTL) responses both in vitro and in vivo against epitopes displayed in multiple 
copies on their surface [ 4], activate T -helper cell s [5] and elicit the production of specific 
antibodies [ 6, 7] all normally without adjuvant. Thus we have selected bacteriophage as a 
platform for eliciting anti -HAAH immune responses. Bacteriophage are ubiquitous and 
essentially innocuous to humans, howev er, as an added safety mechanism, they may be 
neutralized rendering them non -infective to host bacteria while retaining their 
immunostimulant properties. Once neutralized, the bacteriophage effectively becomes a 
nanoparticle, for enhanced delivery of prote in fragments to APC .   
We have designed a bacteriophage lambda system to display HAAH peptides fused at the 
C-terminus of the head protein gpD of phage lambda. The phage carry 200- 300 copies of the 
gpD protein on their head and thus display many copies of an approximately 25 kDa molecular 
weight fragment of HAAH on their surface.  The drug substance is one of these HAAH 
bacteriophage lambda constructs: HAAH -1λ (SNS-301). 
  
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 18 of 47 
 3.2  Previous  Non -Clinical Experience  
Nonclinical studies have focused on the immunogenicity and efficacy of the HAAH 
Nanopart icle Vaccine in rodent models. Nonclinical toxicology studies have been completed 
and are described below . 
The nonclinical data generated to date include:  
• Demonstration of immunogenicity in mice and rats  
• Demo nstration of dose response to both amount of vaccine and number of doses  
• Demonstration of both humoral and cellular immunity  
• Demonstration of enhanced immunogenicity for intradermal compared to 
intramuscular immunization 
• Efficacy data in three rodent tumor  models, including solid tumors and metastases  
o Inhibition of solid tumor growth and metastases with the mouse hepatocellular 
carcinoma cell line, BNLT3  
o Inhibi tion of solid tumor growth, lung metastases and mortality with the mouse 
breast cancer cell line , 4T1 
o Inhibition of metastases with the rat prostate cancer cell line, MLLB -2 
The data listed  above have been generated in three laboratories, which provide  corroboration 
of the nonclinical observations in multiple environments and w ith multiple technical st aff. It 
is important to note that there ha s been no local reactogenicity or adverse events  (AEs)  
associated with the administration of multiple doses of the HAAH Nanopar ticle Vaccine in 
mice and rats.  These vaccines are immunogenic, show efficacy in three  tumor model systems 
and are safe in the doses given to rodents. In total, the data strongly support the potential utility 
of the HAAH -1λ vaccine for the immunotherapy of cancer.  
It is anticipated that the HAAH Nanoparticle Vaccine will also prove to be safe in humans.  
Bacteriophages are ubiquitous in our environment. All humans are constantly exposed to large 
numbers of bacteriopha ge with no apparent harm. The relatively low dose  and dose frequency 
of a vaccine as compared to other cancer drugs, both chemical and biological, also predict that 
these materials should be quite safe in human subjects.   
Panacea has conducted a repeated dose study in rats that assessed the toxicity  of the SNS-301 
(previously named PAN -301-1) HAAH n anoparticle vaccine when administered 
intradermally at the same three dose levels (2 x 1010, 1 x 1011 and 3 x 1011 particles) and same 
dose schedule (3 doses given at 21 day intervals) as proposed for this hum an study , followed 
by 2 week and 4- week  recovery periods .  These dose levels were chosen based on 
demonstrated immunogenicity and efficacy in the animal models described above. The 
conclusions of the study were that treatment with SNS -301 at doses up to 3 x 1011 particles 
had no effect on mortality, physical examinations, cage -side observations, dermal Draize 
observations, body weights or body weight changes, food consumption, body temperature, 
ophthalmologic observations, gross pathology, absolute and rela tive organ weights, 
hematology or clinical chemistry.  A slightly prolonged  but non- adverse PT time in males 
given > 1 x 1011 particles and females given 3 x 1011 particles persisted through the first 
recovery period (2 weeks post -3rd injection).  The prolonged PT time resolved in males by the 
second recovery period (4 weeks post -3rd injection) but remained minimally prolonged in 
females given 3 x 1011 particles .  Test article- related microscopic findings were present in the 
injection site in animals given >  1 x 1011 particles and consisted of mild or moderate 
mononuclear or mixed inflammatory cell infiltrates in the dermis and/or subcutis.  These 
findings were considered non- adverse and resolved during recovery.   Additionally, the SNS -
301 vaccine demonstrated a significant antibody response that was dependent on both the dose 
level and number of doses administered.  
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 19 of 47 
 These toxicology results  demonstrat e safety of the SNS-301 HAAH n anoparticle vaccine and 
support the planned multiple dose  Phase 1 study of the HAAH Nanoparticle Vaccine in 
humans described in this protocol.  
3.3 Current Clinical Experience  
Review of Current Clinical Data with SNS -301 
Exposure  
A total of 12 patients have been treated with at least 5 doses of SNS -301.  All 12  of these 
patients are subjects in the current IND protocol ..  Seven  patients in the current study have 
already received 9 or more injections and will continue to receive treatment until the current 
amendment limiting dosing to 9 doses becomes effect ive. The listing of patient identifiers, 
primary cancer data, and exposur e data are provided in Table 2. 
Table 2 : Patients Treated with SNS -301 
Patient ID  IND Study 
(Y/N)  Primary Cancer  Date of 
First Dose  Dose 
Administered  Number of 
Doses  
001-001 Yes Prostate  1/5/17  2.0 x 1010 
1.0 x 1011 
3.0 x 1011 11 
5 
6 
004-001 Yes Prostate  4/19/17  2.0 x 1010 
1.0 x 1011 
3.0 x 1011 7 
5 
7 
004-002 Yes Prostate  5/23/17  2.0 x 1010 
1.0 x 1011 
3.0 x 1011 5 
5 
7 
004-004 Yes Prostate  6/20/17  1.0 x 1011 
3.0 x 1011 9 
7 
004-003 Yes Prostate  7/18/17  1.0 x 1011 
3.0 x 1011 7 
2 
003-002 Yes Prostate  7/25/17  1.0 x 1011 
3.0 x 1011 6 
5 
001-003 Yes Prostate  8/21/17  3.0 x 1011 12 
003-006 Yes Prostate  11/13/17  3.0 x 1011 8 
004-006 Yes Prostate  11/20/17  3.0 x 1011 8 
004-007 Yes Prostate  11/29/17  3.0 x 1011 8 
001-004 Yes Prostate  12/20/17  3.0 x 1011 7 
003-007 Yes Prostate  1/29/18  3.0 x 1011 5 
 
 
 
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 20 of 47 
 Local Tolerability  
Local tolerability of the drug administration is being evaluated after each dose at 1 hour, 7 
days and after each new injection.  The assessment of injection site reactions includes the 
evaluation of injection site pain, tenderness, erythema, erythema wheal measurement, 
swelling, and swelling wheal measurement. A total of 1 42 doses of SNS -301 have been 
administered to these 12 patients. In all cases, there have been no reports of a local injection 
site reaction immediately (1hr) following the first injectio n, at day 7 post injection, or 
following the second and subsequent injections.  
Biochemical Safety  
In the IND study patients, biochemistry, hematology, and PT/PTT/INR are measured pre -dose, 
at Day 8, Day 15, and Day 22 just prior to the second dose of study drug on an ongoing basis 
for each cycle of study drug. Patients treated compassionately have blood testing performed 
per the standard of investigator care. There have been no clinically significant changes in any 
analyte measured in the IND -treated patie nts over the course of the study. Further, there have 
been no reports of any laboratory abnormalities in patients receiving compassionate use SNS -
301. 
CH50 Complement  
Total complement (CH50) has been determined pre -treatment for each new dose, at D ay 8, 
Day 15, and D ay 22 prior to the next dose. There were no clinically relevant changes in CH50 
acutely ( Day 8) or chronically every 22 days following multiple administrations of study drug.  
Clinical Safety  
There have been no serious adverse events reported in any of the 12 patients exposed to SNS -
301.  Three patients have experienced a total of 5 adverse events deemed to be possibly related 
to study drug as outlined in Table 3. All AEs are ≤ G rade 3.   
Table 3 : Adverse Events  
Patient Number  Adverse Event  Date  Dose  
001-001 Migratory Arthralgia  9/4/17  1.0 x 1011 
001-001 Migratory Arthralgia  11/20/17  1.0 x 1011 
001-001 Migratory Arthralgia  12/11/17  1.0 x 1011 
001-004 Erythema  12/22/17  3.0 x 1011 
003-002 Shortness of breath  12/06/17  1.0 x 1011 
 
Dose Limiting Toxicities  
There have been no dose -limiting toxicities reported in the IND treated patients and no drug 
related events of any grade in the compassionate use treated patients.  
Progression  
To date, none of the SNS -301 treated patients have experienced disease progression. Table 4 
lists the patients and their current progression free interval.  
  
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 21 of 47 
 Table 4 : : Progression Free Intervals  
Patient ID  IND 
Study 
(Y/N)  Primary 
Cancer Date of First 
Dose  Progressive 
Disease (Y/N)  Current 
Progression Free 
Interval 
(months) 
001-001 
Yes Prostate  1/5/17  No > 15 
004-001 
Yes Prostate  4/19/17  No > 11 
004-002 Yes Prostate  5/23/17  No > 11 
004-004 Yes Prostate  6/20/17  No >10 
004-003 Yes Prostate  7/18/17  No >9 
003-002 Yes Prostate  7/25/17  No >9 
001-003 Yes Prostate  8/21/17  No >8 
003-006 Yes Prostate  11/13/17  No >5 
004-006 Yes Prostate  11/20/17  No >5 
004-007 Yes Prostate  11/29/17  No >5 
001-004 Yes Prostate  12/20/17  No >4 
003-007 Yes Prostate  1/29/18  No >3 
Conclusion  
While still early in the study, these data taken together suggest that SNS -301 is well tolerated, 
does not result in local injection site reactivity, and does not appear to result in dose limiting 
toxicities or metabolic complication.  
3.4 Study Rat ionale  
Oncology trials frequently employ dose -escalation using a 3+3 schema; it is considered 
standard practice for determining the MTD  of a particular study treatment in humans. The 
starting dose for such studies is usually calculated from the results of toxicology studies, which 
are often not performed in humans [8]. In this study, the starting dose and the subsequent dose 
escalations were determined from the results of a repeated dose toxicology study conducted in 
rats that evaluated the same 3 intraderm al doses and dose frequency for the SNS-301 as 
proposed here. Only minimal toxicologic effects were observed in the animals at the higher 
two dose levels and these were resolved through the 2 - and 4- week recovery periods (see 
Section 3.2 ). 
The selection rationale for the specific dose levels proposed for this study is based on the in 
vivo results of this range of doses in mice and rats that have shown both immunogenicity and 
efficacy of the SNS -301 vaccine.  The vaccine has demonstrated immunogenicity in rats by 
IgG antibody response to recombinant HAAH and to the recombinant bacteriophage HAAH -
1λ drug substance at each dose level, 2 x 1010, 1 x 1011 and 3 x 1011 particles.  This antibody 
response i s both dose level -dependent and dose number -dependent.  In mice, dose levels of 
approximately 2 x 1010 to 3 x 1011 particles have also demonstrated immunogenicity in a 
similar dose level - and dose number -response manner in multiple studies.  Furthermore, S NS-
301 vaccine doses up to 3 x 1011 particles have demonstrated inhibition of solid tumor growth 
and metastases in in vivo mouse tumor models with the mouse hepatocellular carcinoma cell line, BNLT3, and with the mouse breast cancer cell l ine, 4T1 and have  demonstrated inhibition 
of metastases in a rat tumor model with the rat prostate cancer cell line, MLLB -2. 
The dose -escalation phase will be conducted in patients with biochemically relapsed prostate 
cancer because this is a cancer that generally takes a long time to develop. Further, archived 
patient tumor tissue will be tested for the HAAH epitope before enro llment into the study; 
patients who do not test positive for the HAAH epitope in archived tissue or fresh serum 
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 22 of 47 
 sample will not be entered into the treatment phase as they are not deemed suitable candidates 
for the HAAH vaccine .  The 21 -day treatment phase  will allow the patient sufficient time to 
recover from any adverse effects of the vaccine before the next dose.  It is anticipated that the 
SNS-301 will lead to the development of active anti-HAAH immunity with consistent 
polyclonal anti-HAAH antibody tite rs in addition to development of anti -HAAH T -cells. This 
is further supported by our current data from patients treated up to now. Based on this , a 
decision has been made to  limit the total number of injections to 9, which accounts for 
6 months  of treatmen t with an additional 6 months of follow up,  with monthly measurement 
of PSA levels and anti -HAAH immunity parameters. Patients who , at the time of this 
amendment , have received more than 9 injections , will cease treatment at the time of their last 
injection when  this amendment goes into effect and will also be followed for 6 months , as will 
patient s whose disease progression leads to treatment stoppage before 1 year . Patients with 
evidence of progression and decl ining HAAH immune parameters have the option of resuming 
therapy on the study protocol in the 6 month follow up period. All p atients are eligible for 
enrollment in the expanded access protocol  after study closure .  
4. Study Objectives  and Endpoints  
4.1 Study Obje ctives  
4.1.1 Primary   
• To determine the maximum tolerated dose (MTD) of SNS -301 based on the incidence 
of dose -limiting toxicities (DLT) and the maximum administered dose of SNS -301, 
when administered every 21 days in patients  with biochemical ly relapsed prostate 
cancer  
4.1.2 Secondary  
• To assess the overall  safety of SNS -301 
  
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 23 of 47 
 4.2 Study Endpoints  
4.2.1 Primary  
• To determine the MTD  
• Determine the recommended Phase 2 dose ( RP2D ) if different than the MTD  
• Determine the DLTs associated with SNS -301 
4.2.2 Secondary  
• Incidence of administration  site reactions  
• Biochemical safety and tolerability  
• Geometric mean titers of anti -HAAH antibodies by dose  
• Antigen -specific CTL responses by dose  
• Production of B cell and T cell response of interest  
4.2.3 Clinical secondary endpoints   
• Change in the  prostate -specific antigen  (PSA) velocity  
• Reduction in the PSA doubling time from pre -baseline  
4.2.4 Pharm acodynamic secondary endpoints  
• Duration of antigen -specific anti -HAAH antibody titers  
• Changes in the amplitude or duration of the production of anti -HAAH antibodies  
• Correlation of  anti-HAAH titers and serum HAAH levels  
  
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 24 of 47 
 5. INVESTIGATIONAL PLAN 
This is a P hase I, open- label, study of SNS -301, an HAAH -directed  nanoparticle vaccine,  
given intradermally in cohort s of patients  with biochemically relapse prostate cancer,  using a 
fixed dose -escalation schema every 21 days to establish the MTD.   
5.1 Overall Study Design and Plan Description  
Figure 1: Dose -escalation study design (3+3 schema)  
 
 
 
Following informed consent and screening, archived prostate tumor tissue and patient serum 
will be tested for the expression of HAAH. Patients who test positive for HAAH expression  
in either archived tumor tissue  or fresh serum  may be continued in the stud y. Baseline 
biochemical testing ( chemistry, complete blood count  [CBC] , coagulation panel, CH50, and 
PSA) will be obtained prior to study treatment  administration .  
Treatment will consist of single repeated doses of SNS -301 administered every 21 days. A 
traditional 3+3 dose -escalation schema will be used to deter mine the MTD of SNS -301 for 
the first 2 doses and a modified dose-escalation schema with 6 patient s per dose level for the 
remaining dose . Planned doses of SNS -301 are 2.0 x 1010, 1.0 x 1011 and 3.0 x 1011 particles 
per administration  diluted to 1  mL and administered intradermally. Additional patient s will be  
enrolled at the highest dose level until at least 6 patient s can be evaluated  even if no DLTs are 
observed at the dose. Planned treatment may continue for  two additional doses of SNS -301 
administered every 21 days.  Serum and whole blood samples will be obtained on the day of 
study treatm ent administration (Day 1) and 21 days thereafter . In patients who continue to 
receive study treatment , biochemical and immunologic testing will continue every 21 days.  
The MTD will be determined over the first 21 -day interval following a single dose of SNS-
301 in 3 consecutive dose cohorts. The MTD will be considered the dose level lower than that 

Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 25 of 47 
 dose wh ich produces ≥ 2 DLTs  in 3 or 6 patient s. A DLT will be considered a protocol -
specified drug-related grade 3 -4 (National Cancer Institute Common Terminology Criteria for 
Adverse Events [NCI-CTCAE ] V 4.03) adverse experience ) (Section 5.4.5.1 ). The  RP2D will 
be the highest dose administered if  no MTD is observed.  
Dose cohorts will be enrolled sequentially.  
An evaluation period of  at least 21-days for the first patient  (sentinel patient ) in a new cohort 
is required to evaluate tolerability before adding additional patient s to the cohort. If 
safety/tolerability is adequate, then the remaining patients  will be dosed in the cohort.  A 
second evaluation will occur for the last patient  of each cohort of at least 21-days to evaluate 
safety/ tolerability before dose escalation to the next cohort will occur.  E nrollment will be 
held if an  administration  site reaction  (ASR ) of grade 3 or greater (NCI -CTCAE  V4.03) is 
observed until the event resolves.  In the event enrollment is held for an ASR , the Sponsor , 
Medical Monitor  and PI will evaluate the outcome of the ASR  and must agree to continued 
enrollment.  
Dose -escalation will proceed once all patients  in a cohort (unless the MTD is observed) have 
completed a 21- day safety evaluation following the first  dose of study treatment  in the cohort.  
Planned treatment may continue for  an additional 2 extra doses of SNS -301 administered 
every 21 days .  Additional patients will be  enrolled at the highest dose level until at least 6 
patients can be evaluated  even if no DLTs are observed at the dose   In patients who tolerate 
SNS-301, additional treatment may be continued with single doses of SNS-301 at their current 
dose level , to maintain geometric mean titer (G MT) of HAAH antibodies to no less than 4 
times the baseline value for at least six months (9 injections). Treatment will be terminated 
with the 9th injection or will otherwise be terminated at any time upon the observance of PSA 
doubling < 90 days or occur rence of unacceptable toxicity as determined by the Investigator 
(either for that patient or in their dose cohort). After termination, p atients will be followed for 
an additional 6 months with monthly PSA levels and imaging studies as needed.  
Once the MTD/ RP2D is determined, patients receiving ongoing treatment may be escalated 
to that dose for subsequent treatments and receive a maximum of 9  injections. Patients who 
have received more than 9 injections due to the timing of the amendment limiting therapy to  
6 months (9 doses), will be stopped at their last dose received and be followed for 6 months 
as with other patients. These subjects will continue to be followed for safety and biochemical 
PSA monitoring on a monthly basis for 6 months and are eligible to resume SNS -301 in case 
of increases in PSA doubling to < 90 days or other evidence of disease progression and decline 
in immunological parameters.  
Pharmacodynamic:  
Exploratory pharmacodynamic ( PD) analysis will be performed using dose, vaccine- specific 
antibody response ( geometric mean titer ), antigen- specific T and B cell indices, and the 
relative expression of HAAH in each patient’s tumor. The PD will be balanced and optimized 
to the degree of antigen -specific immune response and minimized for the produc tion of 
regulatory immune processes.  
Other Safety:  
Safety endpoints will be evaluated by the incidence and severity of administration  site 
reactions, changes in biochemical safety measures, general incidence and types of AEs, 
serious adverse events (SAEs) , and other overt toxicities.  
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 26 of 47 
 5.2 Selection of Study Population  
5.2.1 Inclusion Criteria  
1. Signed and dated written Ethics Committee approved informed consent  
2. Men aged 21 to 85 years with a histologic diagnosis of prostate cancer with a 
biochemical relapse following d efinitive local therapy (RP or radiation therapy)  
3. Patients are not eligible or are unwilling to receive additional definitive therapy 
following relapse (either RP or radiation therapy)  
4. No prior cytotoxic chemotherapy  for the current cancer  
5. Normal electrocardiogram (ECG) or ECG with no clinically significant findings as 
determined by the Principal Investigator  
6. Presence of biochemically relapsed prostate cancer defined as either: 1)  PSA > 2 
ng/mL 1 year following initial definitive treatment for prostate can cer: or, 2) PSA 
doubling time (greater than 0.2 ng/mL) <  12 months; or, 3) PSA velocity > 2 
ng/mL/year at any time following radical prostatectomy or radiation therapy.  
7. Positive expression of HAAH in either archived tumor tissue (if available)  or fresh 
serum  
8. No clinical or radiologic evidence of distant metastatic disease as measured by pelvic 
MRI or CT scan in addition to bone scan. These studies will need to be performed 
within 56 (+ 7 days) days prior to the start of the study. 
9. No history of immunosuppressive disease  
10. No evidence of active autoimmune disease. Active autoimmune disease is defined as any disease process that has specifically needed administration of immune 
suppressive and or cytoreductive therapy currently or within the last 1 ye ar. 
11. Able and willing to comply with all study procedures  
5.2.2 Exclusion Criteria  
1. PSA doubling time of < 3 months  
2. Participation in a clinical trial within 30 days  prior to enrollment  
3. Prior major surgery or radiation therapy within 4 weeks of enrollment  
4. Any illne ss or condition that in the opinion of the Investigator may affect the safety 
of the patient or the evaluation of any study endpoint  
5. Screening blood counts of the following:  
Hematopoietic:  
Absolute neutrophil count <  1500/μL,  
Platelets < 100,000/μL,  
Hemoglobin <  9 g/dL;  
Liver/Metabolic:  
Alanine aminotransferase (ALT) and aspartate transaminase (AST) > 2.5 × ULN 
range,  
Total bilirubin >  2 × ULN,  
Albumin <  2.8 g/dL;  
Renal:  
Creatinine clearance <  50 mL/min as predicted by the Cockcroft -Gault formula  
6. Subjects whose partners are WOCBP must use an adequate method of birth control 
while on study drug and at least for 3 weeks after discontinuation of study drug  
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 27 of 47 
 7. Current or anticipated concomitant immunosuppressive therapy (excluding non-
systemic inhaled, to pical skin and/or eye drop -containing corticosteroids)  
8. Any concurrent condition requiring the continued use of systemic steroids (see 
above) or the use of immunosuppressive agents including methotrexate. All other 
systemic corticosteroids must be discontin ued at least 4 weeks prior to first study 
treatment  
9. Receipt of any blood product within 1 month of enrollment  
10. Receipt of any vaccine within 4 weeks of enrollment  
11. Active drug or alcohol use or dependence that, in the opinion of the Investigator, 
would inter fere with adherence to study requirements  
12. Been imprisoned or compulsorily detained (involuntarily incarcerated) for treatment 
of either a psychiatric or physical (i.e. infectious disease) illness  
13. Patients who have a history of coagulopathies, thrombosis or who are receiving active 
anticoagulation for any condition, such as but not limited to, artificial heart valves, atrial 
fibrillation, etc.  
14. Any other conditions judged by the Investigator that would limit the evaluation of a subject  
5.2.3 Removal of Patients from Treatment or Assessment  
The patients may withdraw from treatment with study product  if they decide to do so, at any 
time and irrespective of the reason, or this may be the Investigator’s decisi on to protect the 
safety of the patient. All efforts should be made to document the reason for discontinuation 
and this should be documented in the electronic case report form ( eCRF ). 
Other criteria for possible discontinuation are:  
• PSADT < 90 days  
• 
Unacceptable toxicity  as judged by  the Principal  Investigator  
Adverse event s which are dose -limiting toxicities  
Patient is lost to follow -up 
Patients will be followed up according to the study procedures as specified in this protocol up 
to the scheduled date of study completion, or up to recovery or stabilization of a followed- up 
AE, or the initiation of post study treatment, whichever comes last.  
If possible, and after the permanent discontinuation of treatment, the patients will be assessed 
using the procedure normally planned f or the ‘ end of study ’. 
The patients may withdraw from the study follow -up schedule, before study completion if 
they d ecide to do so, at any time and irrespective of the reason, or this may be the 
Investigator’s decision:  
Patients who are lost to follow -up: 
The Investigator should make every effort to re -contact the patient, to identify the reason 
why he/she failed to attend the visit, and to determine his/her health status, including 
at least his/her vital status. Attempts to contact such patients must be documented in 
the patient’s records ( e.g. times and dates of attempted telephone contact, receipt for 
sending a reg istered letter).  
Patients who did not complete the study and for whom no endpoint data are available will 
be considered as lost to follow -up. 
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 28 of 47 
 The statistical analysis plan will specify how these patients lost to follow -up for their 
primary endpoints will be considered.  
5.2.4 Enrollment Holds  
Enrollment will be held if  the subject experiences a grade 3 or greater ASR as determined by 
the Investigator. The subject must be withdrawn from the study if they experience a grade 3 
ASR. Enrollment can be re -started after  agreement between the Principal Investigator, 
Medical Monitor, and the Sponsor.  
Study enrollment will be halted in the event of a death of a subject while on the study or within 
a 30- day period follow study drug exposure regardless of drug relationship. In the event the 
enrollment is halted, a clinical review of the subject case will be made by the Principal 
Investigator, Medical Monitor, and the Sponsor to assess the safety of the medicinal product. 
If the review concludes there is n o association of the death with the study drug, restarting 
enrollment may proceed.  
5.3 Study Treatment  
5.3.1 Treatments Administered  
Subjects will be administered intradermally  the SNS-301 doses of 2.0 x 1010and 1.0 x 1011 
particles per administration  according to the 3+3 dose -escalation schema described herein  and 
for the 3.0 x 1011 particles  per administration dose additional patients  will be  enrolled until at 
least 6  patients  can be evaluated  even if no DLTs are observed at the dose. Planned treatment 
may continue of  additional doses of SNS-301 administered every 21 days.  
5.3.2 Identity of the Study Treatment  
5.3.2.1  Study Treatment  Details  
The HAAH Nanoparticle Vaccine drug substance is a recombinant bacteriophage lambda 
construct that is  engineered to display a fusion protein of phage gpD and a portion of the 
HAAH protein sequence. The HAAH -1λ (SNS-301) construct contains 199 amino acids from 
the N -terminal region ( amino acids  113 – 311) of the molecule.  
The drug substance is characterized by testing that includes appearance, pH, and identity  by 
dot blot using HAAH -specific monoclonal antibody, impurities (bioburden, endotoxin, host 
cell protein), determination of size distribution by particle analysis, quantitation by particle 
analysis, p rotein determination and potency by antigen enzyme -linked immunosorbent assay 
(ELISA ). 
5.3.2.2  Study Treatment  Administration  
The vaccine will be delivered intra -dermally by a single -use 3M® hollow microstructured 
transdermal system (hMTS) device.  
5.3.2.3  Handling and Storage of Study Treatment  
5.3.2.3.1  Packaging and labeling  
The study treatment , SNS-301, will be packaged by the Sponsor , and supplied i n an open- label 
basis.  
The supplies will be labeled as follows:  
• Sponsor’s name and address  
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 29 of 47 
 • Study number  
• Content of the vial  
• Dosing instructions  
• Batch N umber  
• "Caution: New Drug --Limited by Federal (or United States) law to investigational 
use."  
5.3.2.3.2  Storage  
The study drug product is  stored at 2 – 8 °C.  Temperature excursions to <25°C  for less than 
24 hours a re acceptable.  
5.3.2.4  Handling/ Responsibilities  
The study Treatment  administrator must store and administer the study treatment according to 
the instructions provided by the Sponsor . 
All s tudy treatments shall be dispensed in accordance with the Investigator's prescription and 
it is the Investigator's responsibility to ensure that an accurate record of study treatment  issued 
and returned is maintained.  
Any quality issue noticed with the receipt or use of a study treat ment  (deficiency in condition, 
appearance, pertaining document ation, labeling, expiry date, etc.) should be promptly notified 
to the Sponsor , who will initiate a complaint procedure.  
Under no circumstances will the Investigator supply s tudy treatment  to a third party, allow the 
study treatment to be used other than as directed by this Clinical Trial Protocol, or dispose of 
study treatment in any other manner.  
5.3.2.5  Study Investigational Treatment  Management  and Disposal  
All unused study treatments  should be discar ded at the investigational site a nd a destruction 
certificate obtained.  The study treatment  Administrator will submit the copy of Product 
Accountability Log to the Sponsor . 
A potential defect in the quality of the s tudy treatment  may be subject to initiation by the 
Sponsor  of a recall procedure. In this case, the Investigator will be responsible for promptly 
addressing any request made by the Sponsor , in order to recall s tudy treatment  and eliminate 
potential hazards.  
5.3.3 Method of Assigning Patients  to Study Groups  
This is an open- label dose -escalation study; no randomization will occur.  
All patients who sign the informed consent form  (ICF)  will be assigned a patient study 
number. Patient eligibility must be verified by the Investigator . If a patient fails to meet an 
eligibility criterion during the screening period, then the Investigator  will complete a screening 
failure form in the e -CRF.  
The study treatment  will be administered only to patients included in this study following the 
procedures set out in this clinical study protocol. Details of the exact time of administration 
of medication (day/month/ye ar, hour:minute) and the labe ling on SNS -301 vials will also be 
documented in the e -CRF.  
Patient withdrawn from the study retain the same patient number. New patients must  always 
be allotted a new patient number.  
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 30 of 47 
 5.3.4 Selection of Doses for the Study  
This is an open- label study. Sequential cohorts will be enrolled in the order they present . In 
the dose -escalation cohorts, 3 or 6 patients will be treated with successively higher doses of 
SNS-301: 2.0 x 1010, 1.0 x 1011 and 3.0 x 1011 particles  every 21  days.  
5.3.5 Selection and Timing of Dose for Each Patient  
The MTD will be determined over the first 21 -day interval following a single dose of SNS-
301 in 3 dose cohorts. The MTD will be considered the dose level lower than that dose which 
produces ≥ 2 DLT . 
Dose -escalation will proceed when  once all patients in a cohort  (unless the MTD is observed) 
have completed a 21 -day safety evaluation following the first dose of study treatment  in the 
cohort. Multiple  patients can be in screening phase simultaneously, but the  first eligible patient  
able to be treated will be  assigned the next treatment slot that is available for study.  
More specifically, the first patient  of each dose level  will be enrolled and assessed for DLTs  
during cycle 1.  Subsequent patients in a cohort can be enrolled after a 21 -day review for 
tolerability by the Medical Monitor, Sponsor and Investigator (s) has been completed in the 
first patient .  
After evaluation of the safety data of 3 patients in c ycle 1 of the 2.0 x 1010 particles per 
administration dose, if none of the firs t 3 patien ts experiences a DLT, then dose- escalation to 
the next level (1.0 x 1011 particles per administration ) can occur. When one patient shows a 
DLT , an additional 3 patients will be enrolled at the same dose level.  If no more than 1 out of 
6 patients experiences a DLT, patient enrollment to the next dose level can start.   
Patient s who withdraw from the study during cycle 1 (Day 1 – Day 22 pre -dose) for reasons 
other than safety or toxicity will be replaced.  
Subsequent dose -escalation will be conducted in the same manner.  
If the MTD  is not achieved at the dose level of 3.0 x 1011 particles per administration, further 
dose-escalation will not be conducted . Additional patients will be  enrolled at the highest dose 
level until at least 6 patients can be evaluated  even if no DLTs are observed at the dose.  
Although the dose -escalation process is guided by the safety evaluation during c ycle 1, the 
global safety profile of SNS -301 at each dose level will be considered and discussed with the 
Investigator  before increasing doses.  
Planned treatment may continue  for additional  doses of SNS-301, administered every 21 days .   
In patients who tolerate SNS -301, additional treatment may be continued with single doses of 
SNS-301 at their current dose level  every 2 1 days , to maintain geometric mean titer (GMT) 
of HAAH antibodies to no less than 4 times the baseline value for at least six months (9 
injections).  
Treatment will be terminated with the 9th injection or will otherwise be terminated at any time 
upon the observance of PSA doubling < 90 days or occurrence of unacceptable toxicity. After 
termination, p atients will be followed for an additional 6 months with monthly PSA levels and 
imaging studies as needed.  
Once the MTD/RP2D is determined, patients receiving on going treatment may be escalated 
to that dose for subsequent treatments and receive a maximum of 9 injections. Patients who 
have received more than 9 injections due to the timing of the amendment limiting therapy to 
6 months (9 doses), will be stopped at t heir last dose received and be followed for 6 months 
as with other patients. These subjects will continue to be followed for safety and biochemical 
PSA monitoring on a monthly basis for 6 months and are eligible to resume SNS -301 in case 
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 31 of 47 
 of increases in PS A doubling to < 90 days or other evidence of disease progression and decline 
in immunological parameters.  
5.3.5.1  Dose -limiting toxicities  
Any of the following, if judged to be associated with SNS -301 (i.e., possibly- , probably -, or 
definitely related to), will be  considered a DLT  which are based on the NCI-CTCAE V4.03  
criteria : 
1) Grade 4 non- hematological toxicities (excluding alopecia) of any duration  
2) Grade 3 non- hematologic (non- laboratory) toxicity lasting > 3 days despite optimal 
supportive care  
3) Any Grade 3 or Grade 4 non- hematologic laboratory value if: a). Medical 
intervention is required to treat the subject; b), the abnormality leads to 
hospitalization; c). The abnormality persists for >1 week.  
4) Grade 4 hematologic toxicity, other than those specified in cri teria 5 and 6 below , 
lasting > 7 days  
5) Grade 3 or Grade 4 febrile neutropenia of any duration  
6) Grade 3 thrombocytopenia in combination with a grade 3 or greater blood and 
lymphatic system disorder  
7) Grade 3 AST or ALT that is associated with a grade 2 rise in bilirubin  
5.3.5.2  Dose delay or r eduction  
In case of non- DLT AE (grade 2 NCI -CTCAE V4.03 drug related AE), the dosing interval of 
3 weeks can be extended to up 42 days to allow the recovery from a related toxicity and the 
patient will resume at the same dose. If t he patient experiences the same toxicity requiring a 
dose-delay at the subsequent cycle, the patient should be discontinued.  
No sentinel safety assessment will be made;  however, enrollment will be controlled so that a 
21-day observation period is completed on the first  subject  in each cohort before any further 
enrollment is performed. Additionally, enrollment will be held if an ASR  of grade 3 or greater 
is observed until the event resolves. In the event enrollment is held for an ASR , the Sponsor  
and PI will evaluate the outcome of the ASR  and must agree to continued enrollment.  
5.4 Blinding  
This was an open -label  study, so there will be  no blinding of study personnel.  
5.4.1 Prior and Concomitant Treatment  
All treatments being taken by the patients at entry to the study or at any time during the study 
in addition to the study treatment  are regarded as concomitant treatments and must be 
documented in the a ppropriate screen of the e- CRF.  
5.4.1.1  Allowed concomitant treatments  
The following concomitant treatments are permitted during this study:  
• Supportive treatment will be given as medically indicated.  
• Prophylactic antiemetic premedication including corticosteroids and 
5-hydroxytryptamine  3 antagonists.  
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 32 of 47 
 5.4.1.2  Prohibited Medications or Treatments During Study  
Medications such as those listed below are not permitted in the course of the trial:  
• Concurrent treatment with other investigational drugs  
• Concurrent treatment with any other anticancer therapy including radiotherapy  
5.4.2 Study  Treatment  Accountability and Compliance Procedures  
Administration of the study treatment  will be supervised by the Investigator  or 
sub-Investigator . The study treatment  should not be destroyed until the site is contacted by the 
Sponsor  to provide disposition details. The person responsible for drug dispensing is required 
to maintain adequate records of the study treatment . These records (e.g., product 
accountability log) include the date the study treatment  is received from the Sponsor  and 
administered to the patient.  
The person responsible for study treatment  administration to the patient will record precisely 
the date and the time of the study treatment  administration.  
5.5 Safety and Efficacy Variables and Study Assessment s  
Flow chart s for the  study assessments are provided in Table 1. 
5.5.1 Pre-study Assessments  
5.5.1.1  HAAH expression of archived tissue  
After patient  consent is given, archived tumor tissue (if available)  and serum will be tested for 
the expression of HAAH. Patient s who test positive may be enrolled into the study.  
5.5.1.2  HAAH expression in serum  
After patient  consent is given, patient  serum will be tested for the expression of HAAH 
(Section  7.5.3.2 ). Patients  who test positive will be enrolled into the study.  
5.5.2 Study visits and assessments 
The following evaluations will be performed. All procedure dates defined are based on the 
duration (days) from the initial do se of study medication. 
5.5.2.1  Screening period (Day - 56 (+ 7 days)  to Day 0)  
Following patient informed consent,  archived prostate  tumor  tissue and patient serum  will be 
tested for the expression of HAAH. Only patients who test positive for HAAH expression  in 
archived tumor tissue (if available)  or fresh serum  may be continued in the study .  If tumor 
tissue or fresh  serum  is initially negative for HAAH, the patient can be re -screened for the 
study if PSA level have increased over the next 6 months, patient is willing to participate on 
study in the future , and HAAH expression is now positive in serum or tumor tissue  (on retest) .  
If archived tumor tissue is negative on initial testing, the same tumor tissue will not be re-
tested.  
Assessments at Screening:  
• Informed consent administered  
• HAAH expression in archived tumor tissue (if available)  and/or fresh serum  
• Medical/ oncology history, demographics  
• Baseline signs and symptoms  
• Physical examination, vital signs, ECG  
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 33 of 47 
 • Eastern Cooperative Oncology Group (ECOG)  performance score  
• Prostate -specific antigen ( PSA) assessment : if the screening period is between 3 and 
8 weeks prior to first dose, the PSA must be re -tested within 14 days prior to first dose  
• Clinical laboratory tests, chemistry, hematology, coagulation, CH50  if the screening 
period is between 3 and 8 weeks prior to first dose, the labs noted must be re -tested 
within 14 days prior to first dose  
• Pelvic MRI or CT scan in addition to bone scan.  
5.5.2.2  Dose -escalation Treatment: Day 1  
• Immunologic blood collection –  pre-dose on day of drug administration (eg Day 1) 
and 21 days thereafter.  
• Medical/oncology history review  
• Symptom -directed physical examination  
• Prostate -specific antigen (PSA) assessment  
• Vital signs, ECG  
• ECOG score  
• Baseline biochemical testing (chemistry, CBC, coagulation, CH50,) prior to study 
drug administration  
• Study treatment  administration  
• Physician administration  site assessment  (post administration ) 
• Adverse e vents and concomitant medications  
5.5.2.3  Dose -escalation Treatment: Day 8 ± 2 days  
• Symptom -directed physical examination  
• Vital signs  
• ECOG score  
• Biochemical testing:  chemistry, hematology, coagulation, CH50  
• Physician administration site assessment  
• Adverse events , concomit ant medications  
5.5.2.4  Dose -escalation Treatment: Day 15 ± 2 days  
• Symptom -directed physical examination  
• Vital signs  
• ECOG score  
• Clinical laboratory tests, chemistry, hematology, coagulation, CH50  
• Adverse events, concomitant medications  
5.5.2.5  Study V isits: Day 22, Day 43 ± 3 days  
• Immunologic blood collection –  pre-dose on day of drug administration on Day 22, 
43, and every 21 days thereafter if continuing treatment  
• Symptom -directed physical examination  
• Vital signs and ECG  
• Eastern Cooperative Oncology Group (ECOG) performance score  
• Prostate -specific antigen (PSA) assessment  
• Biochemical testing:  chemistry, hematology, coagulation, CH50 
• Evaluation of subject to allow continued dose escalation 
• Study treatment  administration  
• Physician administration  site assessment  (post -administration ) 
• Adverse even ts and concomitant medications  
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 34 of 47 
 5.5.2.6  Additional treatment: E very additional 21 days  ± 3 days  if indicated  
A maximum of 9 drug administrations will be administered on this study for all patients, 
except in the case of progression on study and or in the case of patients who had been on study 
for more than 6 months at the time of this amendment. Patients with evidence of progression 
and declining HAAH immune parameter s within 6 months of stopping therapy have the option 
of resuming therapy on the study protocol.  
• Immunologic blood collection – pre-dose on day of drug administration every 21 days 
thereafter if continuing treatment .  
• Symptom -directed physical examination  
• Vital signs and ECG  
• Eastern Cooperative Oncology Group (ECOG) performance score  
• Prostate -specific antigen (PSA) assessment  
• Biochemical testing: chemistry , hematology, coagulation, CH50 
• Study treatment administration   
• Physician administration site assessm ent (post -administration)  
• Adverse events and concomitant medications  
5.5.2.7  Follow up and End of Study ( EOS): 28 days ± 3 days  after last treatment  for a total 
of 6 months  
• Complete  physical examination  
• Vital signs  
• Eastern Cooperative Oncology Group (ECOG) performance score  
• ECG  
• Prostate -specific antigen (PSA)  assessment  
• Clinical laboratory tests, chemistry, hematology, coagulation, CH50  (only on first 
follow up)  
• Immunologic blood collection  
• Adverse events and concomitant medications  
5.5.3 Safety Measurements  
5.5.3.1  Clinical Laboratory Assessments  
Hematological toxicities will be assessed in term of hemoglobin value, white blood cell, 
neutrophil, platelet and, lymphocyte count according to NCI -CTCAE V4.03 AE grading.  
Laboratory abnormalities (grade 1 and greater that are listed in the NCI -CTCAE  V4.03 ) 
should be recorded on the AE page regardless of their causality. Test analytes are provided in 
the table below.  
 
 
 
 
 
 
 
 
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 35 of 47 
 Hematology  Serum chemistry  
Full and differential blood count  
Hematocrit (Hct)  
Hemoglobin (Hgb)  
Platelet count  
Red blood cell (RBC) count  
White blood cell (WBC) count  with d ifferential  
 Albumin 
Alanine aminotransferase (ALT)  
Aspartate aminotransferase (AST)  
Alkaline phosphatase (ALP)  
Blood Urea Nitrogen (BUN) or Urea  
Carbon dioxide (CO 2) 
Creatinine  
Electrolytes (Na, K, Cl, Ca, P)  
Glucose (either fasting or non- fasting)  
Lactate dehydrogenase (LDH)  
Total bilirubin  
Direct bilirubin  
Total cholesterol  
Triglycerides  
 
Coagulation, CH50  PSA  
Prothrombin ti me (PT)/INR  
Activated partial thromboplastin time 
(PTT)  PSA 
5.5.3.2  Immunological blood collection  
Antigen -specific anti -HAAH antibody titers  
Anti-HAAH antibody  titers from serum samples are determined by ELISA .  Patient sera are 
serially diluted and incubated in microplate wells coated with recombinant HAAH antigen.  
The plates are then incubated with anti -human immunoglobin G ( IgG)-peroxidase conjugate, 
followed by color development to detect the amount of patient IgG bound to the HAAH antigen.  The data are expressed as the reciprocal of the end -point titer.  
Antigen -specific CTL responses  
Cytotoxic  T-cells (CTLs) and APC  will be isolated from patient peripheral blood monocytes 
(PBMCs) by magnetic activated cell sorting (MACS) on the basis of specific cell surface 
markers. APCs will be loaded with antig en (HAAH) for 3 hours and labeled  with a fluorescent 
dye, carboxyfluorescein succinimidyl ester (CFSE) , and incubated with CTLs at varying 
effector to target cell ratios. Cell -mediated cytotoxicity is determined by antigen -specific 
release of dye.  
Cytotoxi c T-Lymphocyte Killing Assay  
Quantitation of specific cell lysis by patient -derived CD8+ T -cells will be determined using a 
flow cytometric assay employing two fluorochromes, 5 - (and 6- ) carboxyfluorescein diacetate 
succinimydyl ester (CFSE) and 7 -amino ac tinomycin D (7- AAD). CFSE is pre -loaded into 
target cells where upon internalization it is covalently linked to intracellular amine groups and 
thus does not leach from cells into the media nor is it transferred to adjacent cells. As such, 
CFSE can be used as a marker to differentiate between effector and target cells in the final 
assay. 7 -AAD is a membrane impermeable dye that when added subsequent to the period of 
cell lysis can only be incorporated only into dead cells (whose membranes have been compromis ed) and thus can be used to differentiate between live and dead cells.  
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 36 of 47 
 Target Cells: Patient derived antigen presenting cells (APCs) will be isolated from peripheral 
blood mononuclear cells (PBMCs) using magnetic assisted cell separation (MACS) 
technology  (Miltenyi Biotec). APCs may be loaded with antigen (HAAH) for 12- 16 hrs. prior 
to use in the CTL assay. Immediately prior to assay, target cells will be loaded with CFSE.  
Effector Cells: CD8+ T -cells will be isolated from peripheral blood mononuclear cel ls 
(PBMCs) using magnetic assisted cell separation (MACS) technology (Miltenyi Biotec).  
Lysis: Effector and target cells will be co -incubated at varying effector to target cell ratios at 
37⁰C for 4 hours. Target cells are held constant at ~25,000 cells per  well of a 96 well plate 
while effector cells will be varied from a ratio of 1:1 with target cells up to 25:1. After 
incubation, cells are labeled with 7- AAD to differentiate between live and dead cells. Cells 
are subsequently analyzed by flow cytometry fo ur staining populations are counted: those that 
stain with both CFSE and 7 -AAD, those that stain with CFSE but not 7- AAD, those that stain 
with 7 -AAD but not CFSE and those that do not stain with either fluorophore. Percent specific 
lysis is determined by taking the ratio CFSE/7 -AAD labeled cells to total CFSE labeled cells. 
The ratio of non- CFSE labeled cells vs. CFSE labeled cells is an indicator of the true effector 
to target cell ratio.  
Measurement of B cell and T cell response  
B cells will be isolated  from patient PBMCs  by magnetic activated cell sorting (MACS) on 
the basis of specific cell surface markers. After several days of growth in culture, medium will 
be tested for antigen -specific anti -HAAH antibody titers as above. 
CD4+ T -cells responses w ill be determined by isolating CD4+ T -cells and APC  from patient 
PBMCs  by magnetic activated cell sorting (MACS) on the basis of specific cell surface 
markers. APCs will be loaded with or without antigen (HAAH) for 3 hours  and coincubated 
with CD4+ T -cells ov ernight. Antigen -specific T -cell activation will be determined by flow 
cytometric measurement of CD154 and interferon γ.  
Measurement of CD4, CD8, CD19 cell populations  
CD4+, CD8+ and CD19+ cell populations as a percentage of total PBMCs will be determined 
by flow cytometry.  
5.5.3.3  Administration  site reaction  
The area around the administration site will be  assessed by the physician for adverse reactions  
at least 30 minutes post study drug administration. The Investigator will grade an y ASR s 
according to the NCI -CTCAE  V4.03 (excluding the actual expected micro- injection 
punctures) .  
Patients will be required to report any change in the administration site a nd return to the clinic 
for evaluation by the Investigator.  
5.5.3.4  ECOG performance score  
The health, activity and w ell-being of the patient was measured by the ECOG performance 
status and was assessed on a scale of 0 to 5 with 0 being fully active and 5 being dead. Full 
details are described in Appendix A . 
5.5.3.5  Adverse Events (AE)  
Adverse event means any untoward medical occurrence associated with the use of a drug in 
humans, whether or not considered drug related and occurs after the patient  is given the first 
dose of study drug .  Any AE that occurs prior to the first dose is part of the medical history.   
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 37 of 47 
 At least 30 minu tes post dose, the Investigator should evaluate the site of drug administration 
and query the patient  in a general manner regarding the presence of any untoward effects.  
Laboratory abnormalities (grade 1 and greater that are listed in the NCI -CTCAE  V4.03) 
should be recorded on the AE page regardless of their causality. Worsening of a pre -existing 
condition is also considered an AE as is the discovery of an abnormal finding during physical 
exam that w as not included in the medical history.  
Patients w ill be encouraged to spontaneously report any AE.  Study personnel will ask 
open- ended questions to obtain information about AEs at every visit.  Date and time of onset 
and resolution (if applicable) of the AE will be documented.  
Causality  
Events will be considered treatment  related if classified by the Investigator as possible, 
probable, or definite ly associated with the use of the drug .  Association of events to the study 
treatment  will be made using the following definitions:  
 
Term  Definition  
Definitely  Not The event is definitely not associated with study treatment . 
Probably Not  The temporal association, patient history, or clinical condition is such that 
the study treatment  is not likely to have had an association with the 
observed event.  
Possible  The event: a) follows a reasonable temporal association with the study 
treatment  administration, but b) could have been produced by the patient’s 
clinical condition or other therapy.  
Probable  The event: a) follows a reasonable temporal association with the study treatment , b) abates upon discontinuation of study treatment , and c) cannot 
be reasonably explained by the patient’s clinical condition or other therapy. 
Definite  The event: a) follows a reasonable temporal association with the study 
treatment , b) abates upon discontinuation of study treatment , c) cannot be 
reasonably explained by the patient’s clinical condition or other therapy, and d) reappears on re -exposure to the study treatment . 
 
Severity  
Signs and symptoms will be graded by the  Investigator using the NCI -CTCAE V4.03 graded 
1-5. Grade refers to the severity of the AE. For events not described in the NCI CTCAE , the 
Investigator  will assign grades as 1= mild, 2=moderate, 3=severe, 4=life- threatening, and 
5=fatal  based on this gener al guideline:  
Grade 1 : Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated.  
Grade 2 : Moderate; minimal, local or noninvasive intervention indicated; limiting age -
appropriate instrumental ADL*  
Grade 3:  Severe or medically significant but not immediately life -threatening; hospitalization 
or prolongation of hospitalization indicated; disabling; limiting self -care ADL**.  
Grade 4:  Life-threatening consequences; urgent intervention indicated.  
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 38 of 47 
 Grade 5:  Death  related to AE.  (Grade 5 (Death) may  not appropria te for some AEs and 
therefore may  not an option.)  
Activities of Daily Living (ADL)  
*Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the 
telephone, managing money, etc.  
**Self -care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, 
taking medications, and not bedridden.  
5.5.3.6  Serious Adverse Event (SAE)  
A serious adverse event  (SAE)  is an AE that:  
• Is fatal  
• Is life -threatening, meaning the patient was, in the view of the Investigator, at 
immediate risk of death from the reaction as it occurred, i.e., it does not include a 
reaction that, had it occurred in a more serious form or progressed, might have caused 
death  
• Is a persistent or significant disab ility or incapacity  or substantial disruption of the 
ability to conduct normal life functions  
• Requires or prol ongs inpatient hospitalization  
• Is a con genital anomaly or birth defect  
Other important medical events may be considered SAEs when, based upon appr opriate 
medical judgment, they may jeopardize the patient and may require medical or surgical 
intervention to prevent one of the outcomes as listed (# 1 -5 above) in this definition. 
All SAEs, including death  due to any cause, that occur  during this study a nd until 30 days 
after the last dose of study treatment , whether or not expected and regardless of causality, must 
be reported to the Medical Monitor immediately  upon discovery of the event, using an SAE 
Form .  
The Medical Monitor will advise the Investigator regarding the nature of any further 
information or documentation that is required.  The Investigator should provide the following documentation at the time of notification if available:  
• SAE Form  
• AE (CRF) page  
• Concomitant and support medication pages  
• Relevant diagnostic reports  
• Relevant laboratory reports  
• Admission notes  
• Hospital discharge summary (when available).  
The Sponsor  must notify FDA and all participating Investigator s (i.e., all Investigator s to 
whom the Sponsor  is providing drug under  its INDs or under any Investigator 's IND) in an 
IND safety report of potential serious risks, from clinical trials or any other source, as soon as 
possible, but in no case later than 15 calendar days after the Sponsor  determines that the 
information quali fies for reporting under paragraph (c)(1)(i), (c)(1)(ii), (c)(1)(iii), or (c)(1)(iv) 
of 21CFR 312.32. T he Sponsor  must identify all IND safety reports previously submitted to 
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 39 of 47 
 FDA concerning a similar suspected adverse reaction, and must analyze the signifi cance of 
the suspected adverse reaction in light of previous, similar reports or any other relevant 
information.  
Serious and unexpe cted suspected adverse reaction   
The Sponsor  must report any suspected adverse reaction that is both serious and unexpected. 
The Sponsor  must report an adverse event as a suspected adverse reaction only if there is 
evidence to suggest a causal relationship between the drug and the adverse event, such as:  
1. A single occurrence of an event that is uncommon and known to be strongly 
associated with drug exposure (e.g., angioedema, hepatic injury, Stevens -Johnson 
Syndrome);  
2. One or more occurrences of an event that is not commonly associated with drug exposure, but is otherwise uncommon in the population exposed to the drug (e.g., tendon  rupture);  
3. An aggregate analysis of specific events observed in a clinical trial (such as known consequences of the underlying disease or condition under investigation or other events that commonly occur in the study population independent of drug therapy)  that 
indicates those events occur more frequently in the drug treatment group than in a concurrent or historical control group.  
Submission of IND safety reports  
The Sponsor  must submit each IND safety report in a narrative format or on FDA Form 3500A 
or in an electronic format that FDA can process, review, and archive. FDA will periodically 
issue guidance on how to provide the electronic submission (e.g., method of transmiss ion, 
media, file formats, preparation and organization of files). The Sponsor  may submit foreign 
suspected adverse reactions on a Council for International Organizations of Medical Sciences 
(CIOMS) I Form instead of a FDA Form 3500A. Reports of overall findings or pooled 
analyses from published and unpublished in vitro, animal, epidemiological, or clinical studies 
must be submitted in a narrative format. Each notification to FDA must bear prominent 
identification of its contents, i.e., "IND Safety Report," and must be transmitted to the review 
division in the Center for Drug Evaluation and Research or in the Center for Biologics 
Evaluation and Research that has responsibility for review of the IND. Upon request from 
FDA, the Sponsor  must submit to FDA any additional data or information that the agency 
deems necessary, as soon as possible, but in no case later than 15 calendar days after receiving 
the request.  
5.5.3.7  Unexpected fatal or life -threatening suspected adverse reaction reports  
The Sponsor  must also notify FDA of any unexpected fatal or life -threatening suspected 
adverse reaction as soon as possible but in no case later than 7 calendar days after the Sponsor 's 
initial receipt of the information.  
5.5.3.8  Clinical Laboratory Assessments  
Hematological  toxicities will be assessed in term of hemoglobin value, white blood cell, 
neutrophil, platelet , and lymphocyte count according to the NCI -CTCAE AE grading.  
Laboratory abnormalities (grade 1 and greater that are listed in the NCI -CTCAE  V4.03) 
should be re corded on the AE page regardless of their causality.  
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 40 of 47 
 5.5.4 Efficacy  (Clinical)  Measurements  
5.5.4.1  PSA assessment  
Rising levels of PSA in serum are associated with prostate cancer [9]. Currently, PSA testing 
of serum is a standard test for indicating further investigation for prostate cancer.   
A cutoff of 4.0 ng/mL has a sensitivity of 67.5- 80% for detecting prostate cancer [10] . 
5.5.4.2  Treatment Failure  
Treatment failure  will be assessed by the observance of PSA doubling less than 90 days or 
unacceptable toxicity  as determined by the Investigator.  
5.6 Data Quality Assurance  
At the study sites, all CRFs will be manually reviewed for completeness by the Sponsor 's 
Clinical Research Associates.  Site Staff will enter the required subject data into the provided 
Code of Federal Regulations ( CFR)  Part 11-compliant electronic data capture (EDC) system.  
Programmed computer edit checks will be run against the database to check for discrepancies and pla usibility of the data.  All issues resulting from the computer -generated checks will be 
resolved according to the Sponsor 's standard data management practices in conjunction with 
the medical monitor, clinical study personnel, and the study Investigator s.  
6. Statistical Methods and Determination of Sample Size  
6.1 Statistical and Analytical Plans  
No formal statistical analysis will be performed, however, statistical derivation of all data will be derived by dose cohort and displayed for inspection.  
For the dose -escalation phase of the study, cohorts of 3 or 6 patients will be screened, 
registered and treated at each dose level. The actual sample size may vary depending on the 
incidence of DLT during Cycle 1 at a given dose level. Once the MTD/RP2D is determined, 
additional patients may be accrued to provide for 6 patients in the MTD cohort. 
Approximately, 18 patients will be screened, registered and treated in the trial.  
The primary safety analysis will assess MTD and AEs, clinical laboratory tests, and 
tolerability, based on the combined evaluation of immunogenicity and incidence of DLTs in 
each patient.  
6.2 Determination of Sample Size  
Cohorts of 3 or 6 patients will be screened and treated at each dose level. The actual sample 
size may vary depending o n the incidence of DLT during the first cycle at a given  dose level. 
Approximately 18 patients will be included and treated in the trial.  
7. Ethics 
7.1 Institutional Review Board (IRB) / Ethics Committee  
Before the start of the study, the study p rotocol, ICF, and/or other appropriate  documents will 
be submitted to the IRB , in accordance with local legal requirements.  It is the responsibility 
of the Investigator to ensure that all aspects of the IRB review are conducted in accordance 
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 41 of 47 
 with current local and U.S. re gulations.  Sensei  and the Investigator must inform each other in 
writing that all ethical and legal requirements have been met before the first patient is enrolled 
at the study site.   
7.2 Ethical Conduct of the Study  
The study will be conducted in accordance  with the ethical principles of the current version of 
the Declaration of Helsinki.  The Sponsor  and Investigator will comply with their 
responsibilities as defined in 21 CFR 312.50- 312.70 and I nternational Conference on 
Harmonization Guidance for Industry : E6 Good Clinical Practice (April 1996).  
7.3 Patient Information and Consent  
The Investigator will obtain informed consent from each patient enrolled in the study, in 
accordance with the U.S. Food and Drug Administration (FDA) regulations 21 CFR 50.20 - 
50.27 and the laws and regulations of the state in which the investigation is being conducted.   
The IRB must approve the ICF to be used by the Investigator.  It is the responsibility of the 
Investigator to ensure that informed consent is obtained from the patient or his/her guardian 
or legal representative before any activity or treatment is undertaken which is not part of 
routine care.  This includes, but is not limited to, the performance of diagnostic, screening, or 
therapeutic procedures and the administration of the first dose of study treatment .  The draft 
version of the ICF will be modified by each site and reviewed and approved in writing by 
Sensei  prior to submission to the IRB.  The terms of the consent and when it was obtained 
must also be documented in the patient’s CRF. A second copy of the current ICF will be 
reviewed and signed by the patient  to allow for patient  re-screen ing on study if archived tumor 
tissue or fresh serum  is initially negative for HAAH.  Over this 6 -month interval, PSA levels 
can be obtained and if they have increased appreciably from the original screening visit and HAAH is positive in serum or t umor tissue, the patient  may be enrolled in the study. The same 
archived tumor tissue will not be retested.  
Should a protocol amendment be made, the subject ICF may be revised to reflect the changes 
of the p rotocol.  If the ICF is revised, it is the responsibility of the Investigator to ensure that 
an amended ICF is reviewed and approved by the IRB and signed by all subjects subsequently 
entered in the study.  
7.4 Protocol Amendments  
Neither the Investigator nor Sensei  will alter this study protocol withou t obtaining the 
agreement of the other.  Amendments will be made only in exceptional cases once the study 
has started at the discretion of Sensei  with the agreement of the Investigator.  Changes must 
be agreed to in writing, and signed, by all parties conc erned.  The changes then become part 
of the study protocol.  Any changes in the protocol, even local/site requirements, will be 
written in an amendment.  The IRB must be informed of amendments and, if necessary, 
approval must be sought for ethical aspects.  Approval of amendments must also be obtained 
from the local regulatory authority, if necessary.  
7.5 Confidentiality  
All local legal requirements regarding data protection will be enforced.  All study findings and 
documents will be regarded as confidential.  The Investigator and members of his/her research 
team must not disclose such information without prior written approval from Sensei .  The 
anonymity of participating patients must be maintained.  Throughout documentation and 
evaluation, the patients will be  identified on CRFs and other documents submitted to Sensei  
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 42 of 47 
 by their initials, birth date, and their patient number.  Documents that are not to be submitted 
to Sensei , and that identify the patient (e.g., the signed ICF), must be maintained in confidence 
by the Investigator.  The patients will be told that all study findings will be stored and handled in strictest confidence, according to local requirements.  Patients will be informed that 
authorized research Investigator s and agents of the FDA, other recog nized regulatory 
authorities, and authorized representatives of the Sponsor , Sensei , have the right to inspect 
their medical records.  
8. Investigators and Study Administrative Structure  
This is a Phase 1 trial involving study centers locat ed in the United Sta tes. The Investigator(s) 
responsible for the conduct of the study at their site, in compliance with this Protocol, are 
identified on the Signature of Agreement Page  (Appendix B ).  
8.1 Sponsor Contacts  
All questions regarding the enrollment of patients, regulat ory requirements for the conduct of 
the study, safety reporting, or study conduct should be addressed to the Medical Monitor:  
8.2 Data Handling and Recordkeeping  
8.2.1 Electronic Case Report Form ( eCRF)  
Electronic c ase report forms will be provided via a Part 11 compliant database ; patients will 
not be identified by name on any study documents.  Each patient shall be identified by the 
patient identifying  number that will be assigned by the Sponsor . 
8.2.2 Maintenance of Study Records  
The Investigator must retain a copy of all study documents, including reports to the IRB, 
regulatory authorities, and Sensei  in accordance with FDA regulations.  
The Investigator must maintain study documents:  
• for a minimum of two years following the date the marketing application (NDA/BLA) is approved for the indication for which the drug was investigated; or,  
• for a minimum of two years following the release date of the final report, if no 
marketing application is to be filed by Sensei , or if the marketing application is not 
approved for the i ndication for which the drug was investigated or is discontinued and 
the FDA has been notified; or,  
• for a minimum of 15 years after the completion or discontinuation of the study to be 
filed in support of the registration in the European Union. 
If the Inve stigator relocates, retires for any reason, or withdraws from the study, the study 
records may be transferred to an acceptable designee, such as another Investigator , another 
institution, or to Sensei .  The Investigator must obtain Sensei ’s written permission before 
disposing of or transferring any records.  
8.3 Final Report  
Upon terminating the study, the Investigator will submit a final report to the IRB in keeping 
with local IRB regulations.  This report should include any deviations from the protocol, the 
number and types of patients evaluated, the number of patients who discontinued, including 
reasons, results of the study, AEs, and a conclusion summarizing the results.  
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 43 of 47 
 If requested by the Investigator, at the completion of the study and following analysis o f the 
data, Sensei  will supply a tabulated listing of data and a final clinical statistical report.  A copy 
of the final study report and corrected CRFs, including a receipt to be returned to the Sensei  
Clinical Monitor, will be provided to each Investigator following its release by Sensei . 
8.4 Publication and Use of Study Findings  
By signing the study protocol, the Investigator agrees with the use of results of the study for 
the purposes of national and international registration, publication, and information for 
medical and pharmaceutical professionals.  If necessary, the authorities will be notified of the 
Investigator's name, address, qualifications, and extent of involvement.  Sensei  will prepare 
an Integrated Clinical/Statistical Report .  Any publication/presentation of data must include 
the entire study population.  Submission of data for publication/presentation will be coordinated and approved by Sensei  in collaboration with the Investigator.  Sensei  will 
determine authorship of any publication by enroll ment in consultation with the principal 
Investigator.  
8.5 Liability and Insurance  
The Sponsor  will take out reasonable third -party liability insurance coverage in accordance 
with all local indemnification requirements.  The civil liability of the Investigator,  the persons 
instructed by him, the hospital, practice, or institute in which they are employed, and the 
liability of the Sponsor  in respect of financial loss due to personal injury and other damage, 
which may arise as a result of the carrying out of this study, are governed by the applicable 
law.  As a precautionary measure, the Investigator, the persons instructed by him and the 
hospital, practice or institute are included in such cover in regards to work done by them in 
carrying out this study to the ext ent that the claims are not covered by their own professional 
indemnity insurance.  The Sponsor  will arrange for patients participating in this study to be 
insured against financial loss due to personal injury caused by the pharmaceutical products 
being te sted or by medical steps taken in the course of the study.  Such insurance is taken out 
by the Sponsor  in accordance with regulations in the country concerned.  To the extent that 
payments are made under such insurance, the right to claim damages from the Sponsor  
extinguishes.  
  
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 44 of 47 
 9. REFERENCE LIST  
1. Jia, S., W.J. VanDusen, R.E. Diehl, N.E. Kohl, R.A. Dixon, K.O. Elliston, A.M. Stern, 
and P.A. Friedman. 1992. cDNA cloning and expression of bovine aspartyl 
(asparaginyl) beta- hydroxylase. The Journal of Biological Chemistry 267:14322-
14327.  
2. Lavaissiere, L., S. Jia, M. Nishiyama, S. de la Monte, A.M. Stern, J.R. Wands, and P.A. Friedman. 1996. Overexpression of human aspartyl(asparaginyl)beta -
hydroxylase in hepatocellular carcinoma and cholangiocarcinoma. The Journal  of 
Clinical Investigation 98:1313 -1323. 
3. Shimoda, M., Y. Tomimaru, K.P. Charpentier, H. Safran, R.I. Carlson, and J. Wands. 
2012. Tumor progression- related transmembrane protein aspartate- beta-hydroxylase 
is a target for immunotherapy of hepatocellular car cinoma. Journal of Hepatology 
56:1129- 1135. 
4. De Berardinis, P., R. Sartorius, C. Fanutti, R.N. Perham, G. Del Pozzo and G. Guardiola. 2000. Phage display of peptide epitopes from HIV -1 elicits strong cytolytic 
responses in vitro and in vivo. Nature Biotechnology 18(8):873- 876. 
5. De Berardinis, P., L. D’Apice, A. Prisco, M.N. Ombra, P. Barba, G. Del Pozzo, S. 
Petukhov, P. Malik, R.N. Perham, and J. Guardiola. 1999. Recognition of HIV -
derived B and T cell epitopes displayed on filamentous phages. Vaccine 17 (11 -
12):1434- 1441. 
6. Di Marzo Veronesse, F., A.E. Willis, C. Boyer -Thompson, E. Appella and R.N. 
Perham. 1994. Structural Mimicry and Enhanced Immunogenicity of Peptide Epitopes Displayed on Filamentous Bacteriophage: The V3 loop of HIV -1 gp120. 
Journal of Molec ular Biology 243(2):167- 172. 
7. Perham, R.N., T.D. Terry, A.E. Willis, J. Greenwood, F. di Marzo Veronesse and E. 
Appella. 1995. Engineering a peptide epitope display system on filamentous 
bacteriophage. FEMS Microbiology Reviews 17(1- 2):25- 31. 
8. Guidance for I ndustry: Estimating the maximum safe starting dose in initial clinical 
trials for therapeutics in adult healthy volunteers. U.S. Department of Health and 
Human Services; Food and Drug Administration Center for Drug Evaluation and 
Research (CDER); July 2005 , Pharmacology and Toxicology 
9. Stamey TA, Yang N, Hay AR, et al. Prostate- specific antigen as a serum marker for 
adenocarcinoma of the prostate. N Engl J Med. Oct 8 1987;317(15):909- 16 
10. (http://emedicine.medscape.com/article/457394- overview#aw2aab6b8
 
11. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy 
activity in solid tumors: immune -related response criteria. Clin Cancer Res. 
2009;15(23):7412–7420.  
12. Stephenson, A., Kattan, M.,   Eastham, J. , Dotan, Z., Bianco Jr, F., Lilja, H., and 
Scardino, P. 2006. Deﬁning Biochemical Recurrence of Prostate Cancer After Radical 
Prostatectomy: A Proposal for a Standardized Deﬁnition. J Clin Oncol 24:3973- 3978.  
  
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 45 of 47 
 10. LIST OF APPENDICES  
Appendix  Title  
A Eastern Cooperative Oncology Group Performance Status 
(ECOG)  
B Principal Investigator Signature of  Agreement Page  
  
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 46 of 47 
 APPENDIX A: ECOG PERFORMANCE S TATUS  
ECOG PERFORMANCE STATUS*  
GRADE  ECOG  
0 Fully active, able to carry on all pre -disease performance without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of 
a light or sedentary nature, e.g., light house work, office work  
2 Ambulatory and capable of all self -care but unable to carry out any work activities. Up 
and about more than 50% of waking hours  
3 Capable of only limited self -care, confined to bed or chair more than 50% of waking 
hours  
4 Completely disabled. Cannot carry on any self -care. Totally confined to bed or chair  
5 Dead  
*As published in: Am. J. Clin. Oncol .: Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., 
McFadden, E.T., Carbone, P.P.: Toxicity And Response Criteria Of The Eastern Cooperative Oncology 
Group. Am J Clin Oncol  5:649 -655, 1982.  
  
Sensei Bio therapeutics , Inc  Study Protocol No. SNS0216 Version 5.0  
 
Version Date: 1 2 June 2018  Confidential  Page 47 of 47 
 APPENDIX B : PRINCIPAL INVESTIGAT OR SIGNATURE OF AGREEME NT 
PAGE  
 
INVESTIGATORS AGREEMENT  
This document is a confidential communication of Sensei Biotherapeutics, Inc.  (Sensei ).  The 
recipient agrees that no unpublished information contained herein will be published or disclosed 
without prior written permission of Sensei .  However, this document may be disclosed to 
appropriate Institutional Review Boards, ethics review committees, or authorized representatives of the Investigator  or of boards of health under the condition that they are requested to respect the 
confidentiality of the document. 
 
The signature of the Principal Investigator below constitutes his/her agreement to com ply with the 
contents of this Protocol.  
 
   
Principal Investigator’s Name   Principal Investigator’s Title  
   
   
Principal Investigator’s Address    
   
Principal Investigator’s Signature   Date  
 